0001213900-21-021984 | 20-F | XBRL Viewer

Print Document View Excel Document

Document And Entity Information	12 Months Ended
Document And Entity Information	Dec. 31, 2020 shares
Document Information Line Items
Entity Registrant Name	Aptorum Group Ltd
Document Type	20-F
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001734005
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity File Number	001-38764
Entity Incorporation, State or Country Code	E9
Entity Interactive Data Current	Yes
Class A Ordinary Shares
Document Information Line Items
Entity Common Stock, Shares Outstanding	11,584,324
Class B Ordinary Shares
Document Information Line Items
Entity Common Stock, Shares Outstanding	22,437,754

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 3,495,231	$ 5,189,003
Restricted cash	130,125	104,170
Digital currencies	1,539	1,539
Accounts receivable	62,221	40,543
Inventories	39,133	34,185
Marketable securities, at fair value	28,384,944	1,063,111
Investments in derivatives	4,289	203,320
Amounts due from related parties		962
Due from brokers	160,337	317,005
Other receivables and prepayments	1,378,996	1,079,043
Total current assets	33,656,815	8,032,881
Property, plant and equipment, net	4,686,323	7,093,035
Operating lease right-of-use assets	547,389
Non-marketable investments	4,079,707	7,112,180
Intangible assets, net	964,857	1,311,683
Amounts due from related parties		50,000
Long-term deposits	296,225	294,606
Other non-current assets		59,833
Total Assets	44,231,316	23,954,218
Current liabilities:
Amounts due to related parties	145,926	41,593
Accounts payable and accrued expenses	3,240,772	2,586,527
Finance lease liabilities current	49,396	46,555
Operating lease liabilities, current	432,600
Total current liabilities	3,868,694	2,674,675
Finance lease liabilities, non-current	47,923	97,319
Operating lease liabilities, non-current	155,121
Loan payables to related parties	2,007,285	6,330,472
Total Liabilities	6,079,023	9,102,466
Commitments and contingencies
EQUITY
Additional paid-in capital	38,247,903	24,887,624
Accumulated other comprehensive income (loss)	53,296	(5,552)
Accumulated deficit	(30,489,126)	(37,555,980)
Total equity attributable to the shareholders of Aptorum Group Limited	41,834,151	16,361,208
Non-controlling interests	(3,681,858)	(1,509,456)
Total equity	38,152,293	14,851,752
Total Liabilities and Equity	44,231,316	23,954,218
Class A Ordinary Shares
EQUITY
Common stock value	11,584,324	6,597,362
Total equity	11,584,324	6,597,362
Class B Ordinary Shares
EQUITY
Common stock value	22,437,754	22,437,754
Total equity	$ 22,437,754	$ 22,437,754

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Class A Ordinary Shares
Ordinary shares par value (in Dollars per share)	$ 1.00	$ 1.00
Ordinary shares authorized	60,000,000	60,000,000
Ordinary shares issued	11,584,324	6,597,362
Ordinary shares outstanding	11,584,324	6,597,362
Class B Ordinary Shares
Ordinary shares par value (in Dollars per share)	$ 1.00	$ 1.00
Ordinary shares authorized	40,000,000	40,000,000
Ordinary shares issued	22,437,754	22,437,754
Ordinary shares outstanding	22,437,754	22,437,754

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue
Healthcare services income	$ 911,509	$ 535,166	$ 383,450
Operating expenses
Cost of healthcare services	(1,015,023)	(794,545)	(318,011)
Research and development expenses	(11,586,923)	(6,939,051)	(3,101,432)
General and administrative fees	(4,853,488)	(7,373,425)	(4,919,626)
Legal and professional fees	(2,854,225)	(3,405,705)	(1,811,770)
Other operating expenses	(877,391)	(220,891)	(560,709)
Total operating expenses	(21,187,050)	(18,733,617)	(10,711,548)
Other income (loss), net
Gain (loss) on investments in marketable securities, net	25,241,556	(81,839)	501,522
Gain on non-marketable investments		1,147,190
(Loss) gain on investments in derivatives, net	(199,031)	87,599	(974,444)
Gain on use of digital currencies		46,717
Gain on extinguishment of convertible debts		1,198,490
Changes in fair value of warrant liabilities		(866,300)	124,726
Interest expense, net	(243,628)	(3,699,672)	(4,458,191)
Rental income	30,894	16,868
Sundry income	365,917	232,460
Total other income (loss), net	25,195,708	(1,918,487)	(4,806,387)
Net income (loss)	4,920,167	(20,116,938)	(15,134,485)
Net loss attributable to non-controlling interests	2,146,687	1,430,176	302,762
Deemed dividend related to warrants down round provision	(755,514)
Net income (loss) attributable to Aptorum Group Limited	$ 6,311,340	$ (18,686,762)	$ (14,831,723)
Net income (loss) per share attributable to Aptorum Group Limited
- Basic (in Dollars per share)	$ 0.20	$ (0.64)	$ (0.53)
- Diluted (in Dollars per share)	$ 0.20	$ (0.64)	$ (0.53)
Weighted-average shares outstanding
- Basic (in Shares)	31,135,882	29,008,445	27,909,788
- Diluted (in Shares)	31,534,473	29,008,445	27,909,788
Net income (loss)	$ 4,920,167	$ (20,116,938)	$ (15,134,485)
Other comprehensive income (loss)
Unrealized loss on investments in available-for-sale securities			(1,122,251)
Exchange differences on translation of foreign operations	58,848	(10,897)	5,345
Other comprehensive income (loss)	58,848	(10,897)	(1,116,906)
Comprehensive income (loss)	4,979,015	(20,127,835)	(16,251,391)
Comprehensive loss attributable to non-controlling interests	2,146,687	1,430,176	302,762
Deemed dividend related to warrants down round provision	(755,514)
Comprehensive income (loss) attributable to the shareholders of Aptorum Group Limited	$ 6,370,188	$ (18,697,659)	$ (15,948,629)

Consolidated Statements of Changes in Shareholders’ Equity - USD ($)	Class A Ordinary Shares	Class B Ordinary Shares	Additional Paid-in Capital Amount	Accumulated deficit Amount	Accumulated other comprehensive income (loss) Amount	Non- controlling interests Amount	Total
Balance, at Dec. 31, 2017	$ 5,426,381	$ 22,437,754	$ 5,294,402	$ (2,547,462)	$ (367,782)	$ (14,045)	$ 30,229,248
Balance, (in Shares) at Dec. 31, 2017	5,426,381	22,437,754
Issuance of initial public offering of ordinary shares on December 17, 2018 at $15.8 per share, net of underwriting discount and offering expenses	$ 761,419		9,536,631				10,298,050
Issuance of initial public offering of ordinary shares on December 17, 2018 at $15.8 per share, net of underwriting discount and offering expenses (in Shares)	761,419
Proceeds from non-controlling interest			51,727			(51,726)	1
Converted from convertible debts	$ 349,469		2,683,839				3,033,308
Converted from convertible debts (in Shares)	349,469
Unrealized loss on investments in available-for-sale securities					(1,122,251)		(1,122,251)
Exchange difference on translation of foreign operation					5,345		5,345
Beneficial conversion feature			5,436,686				5,436,686
Net income (loss)				(14,831,723)		(302,762)	(15,134,485)
Balance, at Dec. 31, 2018	$ 6,537,269	$ 22,437,754	23,003,285	(17,379,185)	(1,484,688)	(368,533)	32,745,902
Balance, (in Shares) at Dec. 31, 2018	6,537,269	22,437,754
Adjustment to opening balance of equity				(1,490,033)	1,490,033
Issuance of shares to non-controlling interest			10,672			(10,672)
Issuance of tokens						300,000	300,000
Reacquisition of convertible bonds			(1,298,490)				(1,298,490)
Disposal of a subsidiary						(75)	(75)
Share-based compensation			1,612,832				1,612,832
Exercise of warrants	$ 60,093		1,559,325				1,619,418
Exercise of warrants (in Shares)	60,093
Exchange difference on translation of foreign operation					(10,897)		(10,897)
Net income (loss)				(18,686,762)		(1,430,176)	(20,116,938)
Balance, at Dec. 31, 2019	$ 6,597,362	$ 22,437,754	24,887,624	(37,555,980)	(5,552)	(1,509,456)	14,851,752
Balance, (in Shares) at Dec. 31, 2019	6,597,362	22,437,754
Issuance of shares to non-controlling interest			25,715			(25,715)
Share-based compensation			1,478,565				1,478,565
Exercise of warrants	$ 313,513		(313,513)
Exercise of warrants (in Shares)	313,513
Issuance of Class A Ordinary Shares and warrants, net of issuance cost	$ 4,120,581		12,661,754				16,782,335
Issuance of Class A Ordinary Shares and warrants, net of issuance cost (in Shares)	4,120,581
Warrant Exchange	$ 540,540		(540,540)
Warrant Exchange (in Shares)	540,540
Exercise of options	$ 12,328		48,298				$ 60,626
Exercise of options (in Shares)	12,328						12,328
Exchange difference on translation of foreign operation					58,848		$ 58,848
Net income (loss)				7,066,854		(2,146,687)	4,920,167
Balance, at Dec. 31, 2020	$ 11,584,324	$ 22,437,754	$ 38,247,903	$ (30,489,126)	$ 53,296	$ (3,681,858)	$ 38,152,293
Balance, (in Shares) at Dec. 31, 2020	11,584,324	22,437,754

Consolidated Statements of Changes in Shareholders’ Equity (Parentheticals)	Dec. 31, 2018 $ / shares
Statement of Stockholders' Equity [Abstract]
Initial public offering of ordinary shares	$ 15.8

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net income (loss)	$ 4,920,167	$ (20,116,938)	$ (15,134,485)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Amortization and depreciation	1,334,661	1,299,618	682,292
Share-based compensation	1,478,565	1,612,832
(Gain) loss on investments in marketable securities, net	(25,241,556)	81,839	(501,522)
Gain on non-marketable investments		(1,147,190)
Loss (gain) on investments in derivatives, net	199,031	(87,599)	974,444
Changes in fair value of warrant liabilities		866,300	(124,726)
Gain on use of digital currencies		(46,717)
Settlement of service fee by tokens and digital currencies	24,000	437,178
Operating lease cost	483,398
Loss on disposal of property, plant and equipment	50,197
Impairment loss of property, plant and equipment	330,445
Impairment loss of intangible assets	200,000
Gain on extinguishment of convertible debts		(1,198,490)
Interest income	(825)	(79,558)	(108,512)
Interest expense and accretion of convertible debts	237,163	3,769,263	4,559,714
Accretion of finance lease obligation	7,290	9,967	6,989
Changes in operating assets and liabilities
Accounts receivable	(21,678)	(37,716)	(2,827)
Inventories	(4,948)	(3,543)	(30,642)
Other receivables and prepayments	(358,365)	(427,541)	(45,911)
Other non-current assets			(179,500)
Long-term deposits	20	55,429	(111,951)
Due from brokers	156,668	501,963	751
Amounts due from related parties	50,962	168,089	(79,204)
Amounts due to related parties	(120,560)	(26,060)	1,004
Accounts payable and accrued expenses	800,960	986,241	58,555
Operating lease liabilities	(457,508)
Net cash used in operating activities	(15,931,913)	(13,382,633)	(10,035,531)
Cash flows from investing activities
Purchase of digital currencies		(200,000)
Purchases of intangible assets		(70,109)	(417,794)
Purchases of property, plant and equipment	(161,314)	(837,062)	(5,646,505)
Proceeds from disposal of property, plant and equipment	1,051,282
Proceeds from sales of investment securities	952,196	999,110	2,312
Disbursement of a loan to a third party		(1,400,000)	(3,000,000)
Repayment of a loan from a third party		1,400,000	3,000,000
Net cash provided by (used in) investing activities	1,842,164	(108,061)	(6,061,987)
Cash flows from financing activities
Loan from related parties	1,000,000	6,330,472
Repayment of loan from related parties	(5,306,558)
Payment for settlement of convertible debts		(13,600,000)
Proceeds from issuance of convertible debts			16,120,400
Proceeds from issuance of Class A Ordinary Shares and warrants	17,497,426		11,054,319
Payments of offering costs	(715,091)		(538,122)
Payments for debt issuance costs			(1,099,316)
Payment of finance lease obligations	(53,845)	(53,843)	(58,332)
Net cash provided by (used in) financing activities	12,421,932	(7,323,371)	25,478,949
Net (decrease) increase in cash and restricted cash	(1,667,817)	(20,814,065)	9,381,431
Cash and restricted cash – Beginning of year	5,293,173	26,107,238	16,725,807
Cash and restricted cash – End of year	3,625,356	5,293,173	26,107,238
Supplemental disclosures of cash flow information
Interest paid	131,554	557,333	606,989
Income taxes paid
Proceeds in broker accounts	952,196	999,110	640,227
Non-cash operating, investing and financing activities
Right-of-use assets obtained in exchange for new operating lease liabilities	1,107,206
Issuance of token in exchange of services		300,000
Net settlement of related party balances			164,973
Equipment acquired through finance lease			239,093
Conversion of convertible debts			3,033,308
Settlement of service fee by tokens and digital currencies	24,000	437,178
Deemed dividend related to warrants down round provision	755,514
Reconciliation of cash and restricted cash
Cash	3,495,231	5,189,003	12,006,624
Restricted cash	130,125	104,170	14,100,614
Total cash and restricted cash shown in the consolidated statements of cash flows	$ 3,625,356	$ 5,293,173	$ 26,107,238

- Definition

Amount of repayment of a loan from a third party.

+ References + Details

Organization

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

ORGANIZATION

1. ORGANIZATION

The consolidated financial statements include the financial statements of Aptorum Group Limited (the “Company”) and its subsidiaries. The Company and its subsidiaries are hereinafter collectively referred to as the “Group”.

The Company, formerly known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September 13, 2010 under the laws of the Cayman Islands with limited liability.

On March 1, 2017, the Company changed from an investment fund with management shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries. After that, the Company has become a biopharmaceutical company. The Company researches and develops life science and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies (collectively, “Aptorum Therapeutics Group”).

Below summarizes the list of the major subsidiaries consolidated as of December 31, 2020:

Name	Incorporation date	Ownership	Place of incorporation	Principle activities
Aptorum Therapeutics Limited	June 30, 2016	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED	May 16, 2017	100%	Hong Kong	Provision of management services to its holding company and fellow subsidiaries
Aptorum Medical Limited	August 28, 2017	93%	Cayman Islands	Provision of medical clinic services
Aptorum Innovations Holding Limited	April 15, 2019	100%	Cayman Islands	Investment holding company
Aptorum Innovations Holding Pte. Limited	June 5, 2019	75%	Singapore	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited	June 30, 2017	80%	Cayman Islands	Research and development of life science and biopharmaceutical products
Claves Life Sciences Limited	August 2, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Nativus Life Sciences Limited	July 7, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Videns Incorporation Limited	March 2, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
mTOR (Hong Kong) Limited	November 4, 2016	90%	Hong Kong	Research and development of life science and biopharmaceutical products
Scipio Life Sciences Limited	July 19, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Signate Life Sciences Limited	August 28, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products

Liquidity

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY

2. LIQUIDITY

The Group reported a net operating loss of $20,275,541 and net operating cash outflow of $15,931,913 for the year ended December 31, 2020. In addition, the Group had an accumulated deficit of $30,489,126 as of December 31, 2020. The Group’s operating results for future periods are subject to numerous uncertainties and it is uncertain if the Group will be able to reduce or eliminate its net losses for the foreseeable future. If management is not able to generate significant revenues from its product candidates currently in development, the Group may not be able to achieve profitability.

The Group’s principal sources of liquidity have been cash, marketable securities and line of credit facility from related parties. As of the date of issuance of the consolidated financial statements, the Group has approximately $2.4 million of restricted and unrestricted cash and approximately $10.7 million of undrawn line of credit facility from related parties. Based upon the current market price of the Group’s marketable securities, it anticipates it can liquidate such marketable securities, if necessary. In addition, the Group will need to maintain its operating costs at a level through strictly cost control and budget to ensure operating costs will not exceed such aforementioned sources of funds in order to continue as a going concern for a period within one year after the issuance of its consolidated financial statements.

The Group believes that available cash, together with the efforts from aforementioned management plan and actions, should enable the Group to meet current anticipated cash needs for at least the next 12 months after the date that the consolidated financial statements are issued and the Group has prepared the consolidated financial statements on a going concern basis.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of presentation and consolidation

The consolidated financial statements of the Group are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company, its direct and indirect wholly and majority owned subsidiaries. All material intercompany balances and transactions have been eliminated in preparation of the consolidated financial statements.

Non-controlling interests

Non-controlling interests represent the equity interests that are not attributable to the Group.

Use of estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as income and expenses during the reporting period. Significant accounting estimates reflected in the Group’s consolidated financial statements include valuation of equity securities, fair value of investments in securities, convertible debts, finance lease, warrants and share options, the useful lives of intangible assets and property, plant and equipment, impairment of long-lived assets, valuation allowance for deferred tax assets, and collectability of receivables. Actual results could differ from those estimates.

Foreign currency translation and transaction

USD is the reporting currency. The functional currency of subsidiaries in the Cayman Islands, Seychelles, Samoa and the United States are USD, the functional currency of subsidiaries in Hong Kong is Hong Kong Dollars (“HKD”), the functional currency of a subsidiary in Singapore is Singapore Dollars (“SGD”), the functional currency of a subsidiary in the United Kingdom is Great British Pound (“GBP”), the functional currency of subsidiaries in Canada is Canadian Dollars (“CAD”), and the functional currency of subsidiaries in Ireland is Euro (“EUR”). An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which it primarily generates and expends cash. The management considered various indicators, such as cash flows, market expenses, financing and inter-company transactions and arrangements in determining the Group’s functional currency.

In the consolidated financial statements, the financial information of the Company and its subsidiaries, which use HKD, SGD, GBP, CAD and EUR as their functional currency, has been translated into USD. Assets and liabilities are translated from each subsidiary’s functional currency at the exchange rates on the balance sheet dates, equity amounts are translated at historical exchange rates, and revenues, expenses, gains, and losses are translated using the average exchange rates for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income or loss in the consolidated statements of operations and comprehensive income or loss.

Cash

Cash consists of cash on hand and bank deposits, which is unrestricted as to withdraw and use.

Restricted cash

Restricted cash represented time deposits pledged for banking facilities.

Digital currencies

Digital currencies represented BitCoin, Ethereum, or other virtual currencies that the Group purchased and used to settle certain token related expenses.

Digital currencies are included in current assets in the consolidated balance sheets. Digital currencies purchased are recorded at cost.

Digital currencies held are accounted for as intangible assets with indefinite useful lives. An intangible asset with an indefinite useful life is not amortized but assessed for impairment annually, or more frequently, when events or changes in circumstances occur indicating that it is more likely than not that the indefinite-lived asset is impaired. Impairment exists when the carrying amount exceeds its fair value, which is measured using the quoted price of the digital currency at the time its fair value is being measured. In testing for impairment, the Group has the option to first perform a qualitative assessment to determine whether it is more likely than not that an impairment exists. If it is determined that it is not more likely than not that an impairment exists, a quantitative impairment test is not necessary. If the Group concludes otherwise, it is required to perform a quantitative impairment test. To the extent an impairment loss is recognized, the loss establishes the new cost basis of the asset. Subsequent reversal of impairment losses is not permitted.

Purchases of digital currencies by the Group are included within investing activities in the consolidated statements of cash flows. The utilization of digital currencies in exchange of services are included within operating activities in the consolidated statements of cash flows and any gains or losses from such use are included in other income (loss) in the consolidated statements of operations. The Company accounts for its gains or losses in accordance with the first in first out (FIFO) method.

Inventories

Inventories are stated at lower of cost and net realizable value. Cost is determined using the weighted average method.

Where there is evidence that the utility of inventories, in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes in price levels, or other causes, the inventories are written down to net realizable value.

Accounts receivable

Accounts receivable are stated at the original amount less an allowance for doubtful receivables, if any, based on a review of all outstanding amounts at period end. An allowance is also made when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of the receivables. The Group analyzes the aging of the customer accounts, historical and current economic trends and the age of the receivables when evaluating the adequacy of the allowance for doubtful accounts.

Marketable securities

Marketable securities are publicly traded stocks measured at fair value and classified within Level 1 and 2 in the fair value hierarchy because the Group either uses quoted prices for identical assets in active markets, inputs that are based upon quoted prices for similar instruments in active markets, or quoted prices for identical assets in markets with insufficient volume or infrequent transaction (less active markets).

Investments in derivatives

Investments in derivatives are warrants measured at fair value, with gains or losses from changes in fair value recorded through earnings. The fair value of these warrants have been determined using the Black-Scholes pricing mode. The Black-Scholes pricing model provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity.

Non-marketable investments

Non-marketable investments are comprising of investments in non-redeemable preferred shares of privately-held companies that are not required to be consolidated under the variable interest or voting models. Non-marketable investments are classified as non-current assets on the consolidated balance sheets as those investments do not have stated contractual maturity dates.

The non-marketable equity securities not accounted for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach as of the transaction date.

Fair value measurement

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market participants would use when pricing the asset or liability.

As a basis for considering such assumptions, a three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:

	●	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

	●	Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

	●	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The hierarchy requires the Group to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Group has estimated the fair value amounts of its financial instruments using the available market information and valuation methodologies considered to be appropriate and has determined that the carrying value of the Group’s cash, restricted cash, accounts receivable, due from brokers, other receivables and prepayments, amounts due from/to related parties and accounts payable and accrued expenses as of December 31, 2020 and 2019 approximate fair value due to the short-term nature of these assets and liabilities.

Property, plant and equipment

Property, plant and equipment is stated at cost less accumulated depreciation and impairment losses. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its existing use. Maintenance, repairs and betterments, including replacement of minor items, are charged to expense; major additions to physical properties are capitalized.

Assets under construction are stated at cost less impairment losses. Cost comprises of cost of laboratory equipment delivered but not ready to be used, together with interest expense capitalized during the period of construction or installation and testing. Capitalization of these costs ceases and the asset concerned is transferred to the appropriate fixed assets category when substantially all the activities necessary to prepare the asset for its intended use are completed.

Depreciation of property, plant and equipment is provided using the straight-line method over their estimated useful lives:

Building		29 years
Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

Upon sale or disposal, the applicable amounts of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or credited to income.

Other non-current assets

Other non-current assets represents laboratory supplies that can be used for more than one year. It is stated at cost less accumulated depreciation and impairment losses. Cost represents the purchase price of the supplies.

Amortization of other non-current assets is provided using the straight-line method over their estimated useful lives. The amortization expenses for the years ended December 31, 2020, 2019 and 2018 are $59,833, $59,834 and $59,833, respectively.

Intangible assets

Indefinite-lived intangible assets are tested for impairment at least annually and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Indefinite-lived intangible assets are impaired if their estimated fair values are less than their carrying values.

Finite-lived intangible assets are carried at cost less accumulated amortization and impairment if any. The finite intangible assets are amortized over their estimated useful life, which is the period over which the assets are expected to contribute directly or indirectly to the future cash flows of the Group. These intangible assets are tested for impairment at the time of a triggering event, if one were to occur. Finite-lived intangible assets may be impaired when the estimated undiscounted future cash flows generated from the assets are less than their carrying amounts.

The Group may rely on a qualitative assessment when performing its intangible asset impairment test. Otherwise, the impairment evaluation is performed at the lowest level of identifiable cash flows independent of other assets.

The Group’s intangible assets mainly consist of computer software, exclusive rights in prepaid patented and unpatented licenses. The prepaid patented licenses are for clinical purpose or further development into other products. Prepaid unpatented license is for further development, once the associated research and development efforts are completed, the prepaid unpatented license will be reclassified as a finite-lived asset and is amortized over its useful life. The estimated useful life of the exclusive rights in using patents is generally the remaining patent life from the acquisition date to expiration date under the law, which is 17 to 20 years, the Group will reassess the remaining patent life on annual basis, and the Group will assess the intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable.

Impairment of long-lived assets

The Group reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events occur, the Group measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow is less than the carrying amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over the fair value of the assets, using the expected future discounted cash flows.

Convertible debts

The Group determines the appropriate accounting treatment of its convertible debts in accordance with the terms in relation to the conversion feature, call and put option, beneficial conversion feature (“BCF”) and settlement feature. After considering the impact of such features, the Group concluded that, the convertible debts contained a contingent beneficial conversion feature, which shall not be recognized in earnings until the contingency is resolved, and therefore accounted for such instrument as a liability in its entirety.

Convertible debts were subsequently measured at amortized cost, using the effective interest rate method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in interest expense in the consolidated statements of operations.

Management concluded that the contingency was effectively resolved upon the completion of the IPO on December 17, 2018 so that part of the convertible debts were converted automatically accordingly. The BCF derecognized upon automatic conversion was recorded as interest expense with a corresponding increase to additional paid-in capital. The remaining BCF was recorded as debt discount, which was amortized through the maturity of the convertible debts, with a corresponding increase to additional paid-in capital.

On April 24, 2019, the Group repurchased its convertible debts at approximately $13.6 million with carrying amount of approximately $13.5 million and a gain on extinguishment on convertible debts of approximately $1.2 million was recognized. The repurchasing of convertible debts is considered an extinguishment and the difference between the repurchasing price of debt, the net carrying amount of the extinguished debt and the intrinsic value of BCF is recognized in the consolidated statements of operations. The intrinsic value of BCF of approximately $1.3 million at the extinguishment date was recorded as a reduction of additional paid-in capital.

Deferred offering costs

Deferred offering costs consist principally of legal and registration costs in connection with the Group’s public offering. Such costs are deferred until the closing of the offering, at which time the deferred costs are offset against the offering proceeds and charged to additional paid-in capital.

Operating leases

Prior to the adoption of Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance including ASU No. 2017-13, ASU No. 2018-10, ASU No. 2018-11, ASU No. 2018-20, and ASU No. 2019-01 (collectively, “Topic 842”), operating leases were not recognized on the consolidated balance sheets, instead, rental expenses with fixed payments were recognized on a straight-line basis over the lease term.

Effective January 1, 2020, the Group adopted Topic 842 using a modified retrospective transition approach for leases that exist at, or are entered into after January 1, 2020, and has not recast the comparative periods presented in the consolidated financial statements. At the inception of a contract, the Group determines if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Group’s option to extend (or not to terminate) the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.

The Group has elected not to recognize right-of-use assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases on a straight-line basis over the lease terms.

Finance lease

Leases that transfer substantially all the rewards and risks of ownership of assets to the Group, other than legal title, are accounted for as finance leases. At the inception of a finance lease, the cost of the leased asset is capitalized at the present value of the minimum lease payments and recorded together with the obligation, excluding the interest element, to reflect the purchase and financing. Assets held under capitalized finance leases are included in property, plant and equipment, and depreciated over the shorter of the lease terms and the estimated useful lives of the assets. The interest expenses of such leases are charged to the consolidated statements of operations to provide a constant periodic rate of charge over the lease terms.

Warrants

In connection of the issuance of Class A Ordinary Shares, the Company may issue warrants to purchase Class A Ordinary Shares. Warrants classified as equity are initially recorded at fair value and subsequent changes in fair value are not recognized as long as the warrants continue to be classified as equity.

Revenue recognition

Revenue is recognized when (or as) the Group satisfies performance obligations by transferring a promised goods or services to a customer. Revenue is measured at the transaction price which is based on the amount of consideration that the Group expects to receive in exchange for transferring the promised goods or services to the customer. Revenue from healthcare services is measured upon the provision of the relevant services.

Cost of healthcare services

Cost of healthcare services rendered represents cost in relation to the medical services provided including the compensation of the physicians and cost of pharmaceutical supplies and medicine.

Research and development expenses

Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including amortization of the patent license, depreciation of laboratory equipment, costs of engaging external consultants, advisors and contracted research organization to conduct preclinical development activities and trials, and sponsored research expenses to universities and research institutions.

Income taxes

The Group accounts for income taxes under the asset and liability method. Under this method, deferred income taxes are determined based on differences between the financial carrying amounts of existing assets and liabilities and their tax bases. Income taxes are provided for in accordance with the laws of the relevant taxing authorities.

A valuation allowance is provided for deferred tax assets if it is more likely than not that these items will either expire before the Group is able to realize their benefits, or that future deductibility is uncertain. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

Uncertain tax positions

The Group accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized and recorded as necessary in the provision for income taxes. The Group recognizes interest on non-payment of income taxes and penalties associated with tax positions when a tax position does not meet more likely than not thresholds be sustained under examination. The tax returns of the Group’s Hong Kong subsidiaries are subject to examination by the relevant tax authorities. According to the Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed or has been assessed at less than the proper amount, the statute of limitation is extended to ten years if the underpayment of taxes is due to fraud or willful evasion. According to United Kingdom, Singapore, the United States and Samoa tax rule, trading losses are available to be carried forward indefinitely. According to the Seychelles tax rule, net operating losses are available to be carried forward for 5 years. The Group did not have any material interest or penalties associated with tax positions for the years ended December 31, 2020, 2019 and 2018, and did not have any significant unrecognized uncertain tax positions as of December 31, 2020 and 2019. The Group does not believe that its assessment regarding unrecognized tax benefits will materially change over the next twelve months.

Comprehensive income or loss

U.S. GAAP generally requires that recognized revenue, expenses, gains and losses be included in net income or loss. Although certain changes in assets and liabilities are reported as separate components of the equity section of the consolidated balance sheets, such items, along with net income or loss, are components of comprehensive income or loss. The components of other comprehensive income or loss consist of exchange differences on translation of foreign operations.

Net income or loss per share

Basic net income or loss per share is computed by dividing net income or loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income or loss per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their effect would be anti-dilutive.

Risks and uncertainties

The Group is subject to a number of risks associated with companies at a similar stage, including dependence on key individuals, competition from similar services and larger companies, volatility of the industry, ability to obtain regulatory clearance, ability to obtain adequate financing to support growth, the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Group and general economic conditions.

Recently adopted accounting pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (“ASU 2016-02”), which requires a lessee to recognize a right-of-use asset and a lease liability for operating leases, initially measured at the present value of the future lease payments, in the balance sheet. ASU 2016-02 also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Upon the adoption effective on January 1, 2020, the Group recognized operating lease right-of-use assets of $959,641, and operating lease liabilities of $982,288 in the consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). ASU 2017-11 no longer requires the Group to consider down round features when determining whether its warrant and embedded conversion option is indexed to its own stock. The Group adopted this standard effective on January 1, 2020. The adoption does not have a material impact on the Group’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which amends ASC 820, Fair Value Measurement. This ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Group adopted this standard effective on January 1, 2020. The removed and modified disclosures are adopted on a retrospective basis and the new disclosures are adopted on a prospective basis. The adoption does not have a material impact on the Group’s consolidated financial statements.

Recently issued accounting standards which have not yet been adopted

The Group is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2010 (the “JOBS Act”). Under the JOBS Act, the emerging growth companies (“EGCs”) can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”). Subsequently, the FASB issued ASU 2019-05, Financial Instruments- Credit Losses (Topic 326): Targeted Transition Relief. The amendments in ASU 2016-13 update guidance on reporting credit losses for financial assets. These amendments affect loans, debt securities, accounts receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Group is currently evaluating the impact on its financial statements of adopting this guidance.

In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): “Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which simplifies the accounting for income taxes. This standard will be effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022, on a prospective basis, and early adoption is permitted. The Group is currently evaluating the impact of the new standard on its consolidated financial statements.

The Group does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated balance sheets, consolidated statements of operations and cash flows.

Revenue

12 Months Ended

Dec. 31, 2020

Revenue [Abstract]

REVENUE

4. REVENUE

The Group adopted ASC 606 using the modified retrospective method as applied to customer contracts that were not completed as of January 1, 2019. As a result, financial information for reporting periods beginning after January 1, 2019 are presented under ASC 606, while comparative financial information has not been adjusted and continues to be reported in accordance with the Group’s historical accounting policy for revenue recognition prior to the adoption of ASC 606.

For the years ended December 31, 2020, 2019 and 2018, all revenue came from provision of healthcare services in Hong Kong.

Investment and Fair Value Measurement

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

INVESTMENT AND FAIR VALUE MEASUREMENT

5. INVESTMENT AND FAIR VALUE MEASUREMENT

Assets Measured at Fair Value on a Recurring Basis

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2020 and 2019:

December 31, 2020	Level 1		Level 2		Level 3		Total
Current Assets
Marketable securities
Common stocks	$	66,062	$	28,318,882	$	-	$	28,384,944
Investments in derivatives
Warrants		-		-		4,289		4,289
Total assets at fair value	$	66,062	$	28,318,882	$	4,289	$	28,389,233

December 31, 2019	Level 1		Level 2		Level 3		Total
Current Assets
Marketable securities
Common stocks	$	806,778	$	256,333	$	-	$	1,063,111
Investments in derivatives
Warrants		-		-		203,320		203,320
Total assets at fair value	$	806,778	$	256,333	$	203,320	$	1,266,431

The following is a reconciliation of Level 3 assets measured and recorded at fair value on a recurring basis during the years ended December 31, 2020 and 2019:

	Warrants
Balance at January 1, 2020	$	203,320
Change in unrealized depreciation		(199,031	)
Balance at December 31, 2020	$	4,289
Net change in unrealized depreciation relating to investments still held at December 31, 2020		(198,549	)

Balance at January 1, 2019	$	115,721
Change in unrealized appreciation		87,599
Balance at December 31, 2019	$	203,320
Net change in unrealized appreciation relating to investments still held at December 31, 2019		87,599

The following table presents the quantitative information about the Group’s Level 3 fair value measurements of investment as of December 31, 2020 and 2019, which utilized significant unobservable internally-developed inputs:

December 31,
2020

Valuation technique

Unobservable input

Range

(weighted average)

Warrants

Black-Scholes Model

Estimated time to exit Historical Volatility

6 months 122%

December 31,
2019

Valuation technique

Unobservable input

Range

(weighted average)

Warrants

Black-Scholes Model

Estimated time to exit Historical Volatility

12-18 months 73% - 301%

Non-marketable investments

The Group’s non-marketable investments are investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as the measurement alternative) or for impairment. Any changes in carrying value are recorded within other income (loss), net in the consolidated statements of operations.

The following is a summary of unrealized gains and losses recorded in other income (loss), net, and included as adjustments to the carrying value of non-marketable investments held as of December 31, 2020, 2019 and 2018 based on the observable price in an orderly transaction for the same or similar security of the same issuers:

	Year ended December 31, 2020		Year ended December 31, 2019		Year ended December 31, 2018
Upward adjustments	$	-	$	1,017,468	$	-
Total unrealized gain for non-marketable investments	$	-	$	1,017,468	$	-

The Group did not record any realized gains or losses for the non-marketable investments measured at fair value on a non-recurring basis during the years ended December 31, 2020, 2019 and 2018.

The following table summarizes the total carrying value of the non-marketable investments held as of December 31, 2020 and 2019 including cumulative unrealized upward and downward adjustments made to the initial cost basis of the investments:

	December 31, 2020		December 31, 2019
Initial cost basis	$	4,079,707	$	6,094,712
Upward adjustments		-		1,017,468
Total carrying value at the end of the year	$	4,079,707	$	7,112,180

For the year ended December 31, 2020, non-marketable investments with initial cost of $2,015,005 and accumulated upward adjustments of $1,017,468 were transferred into marketable securities, at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Other Receivables and Prepayments

12 Months Ended

Dec. 31, 2020

Other Income and Expenses [Abstract]

OTHER RECEIVABLES AND PREPAYMENTS

6. OTHER RECEIVABLES AND PREPAYMENTS

Other receivables and prepayments as of December 31, 2020 and 2019 consisted of:

	December 31, 2020		December 31, 2019

Prepaid insurance	$	82,060	$	154,011
Prepaid service fee		174,114		296,565
Rental deposits		12,022		8,584
Prepaid rental expenses		14,251		37,169
Prepaid research and development expenses		978,044		453,634
Other receivables		74,176		109,714
Others		44,329		19,366
	$	1,378,996	$	1,079,043

Digital Currencies

12 Months Ended

Dec. 31, 2020

Digital Currencies [Abstract]

DIGITAL CURRENCIES

7. Digital Currencies

The following table presents additional information about digital currencies:

	December 31, 2020		December 31, 2019

Beginning balance	$	1,539	$	-
Purchase of digital currencies		-		200,000
Utilization of digital currencies to settle service fee		-		(245,178	)
Gain on use of digital currencies		-		46,717
Ending balance	$	1,539	$	1,539

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT, NET

8. PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment as of December 31, 2020 and 2019 consisted of:

	December 31, 2020		December 31, 2019

Building	$	-	$	1,488,396
Computer equipment		77,611		76,365
Furniture, fixture, and office and medical equipment		262,664		271,009
Leasehold improvements		542,514		665,546
Laboratory equipment		4,058,538		4,029,640
Motor vehicle		239,093		239,093
Assets in construction		1,899,169		1,899,169
		7,079,589		8,669,218
Less: accumulated depreciation		2,393,266		1,576,183
Property, plant and equipment, net	$	4,686,323	$	7,093,035

Depreciation expenses for property, plant and equipment amounted to $1,128,867, $1,071,799 and $497,908 for the years ended December 31, 2020, 2019 and 2018, respectively.

For the year ended December 31, 2020, the Group recorded $330,445 of impairment loss of buildings in other operating expenses due to the management assessed that its carrying amount may not be recoverable. On July 20, 2020, the Group signed a sales and purchase agreement to sell its property in Fo Tan, Hong Kong, at approximately $1.1 million to a third party buyer. The property was assigned to the buyer on September 1, 2020.

As a result of the relocation of office, the Group disposed certain leasehold improvement and furniture, fixture, and office equipment in the old office and incurred a disposal loss of $50,197 in other operating expenses for the year ended December 31, 2020.

Intangible Assets, Net

12 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS, NET

9. INTANGIBLE ASSETS, NET

	December 31, 2020		December 31, 2019
Gross carrying amount
Prepaid unpatented license	$	-	$	200,000
Prepaid patented licenses		1,322,820		1,322,820
Computer software		26,985		97,462
		1,349,805		1,620,282

Less: accumulated amortization
Prepaid patented licenses		360,212		257,619
Computer software		24,736		50,980
		384,948		308,599

Intangible assets, net
Prepaid unpatented license		-		200,000
Prepaid patented licenses		962,608		1,065,201
Computer software		2,249		46,482
Intangible assets, net	$	964,857	$	1,311,683

As of December 31, 2020 and 2019, the Group has capitalized seven of the exclusive licenses which includes seven patented and one unpatented technologies in relation to the Group’s therapeutics segment. Pursuant to the license agreements, the Group paid upfront payments and became the exclusive licensee to prosecute certain patents developed or licensed under the applicable agreements.

The Group recognized the prepaid unpatented license to reflect the fair value of the subsidiaries as of the date of the change in status from an investment company to an operating entity. The Group capitalizes the prepaid patented license for the exclusive rights with completed filing of patents in certain jurisdictions (e.g., the United States of America and Europe) and alternative future uses. An impairment loss of $200,000 was recognized in research and development expenses for the year ended December 31, 2020 as the Group considered that the carrying amount of an intangible asset related to an unpatented license may not be recoverable. This license agreement was terminated on February 19, 2021.

Prepaid unpatented license is indefinite-lived intangible assets which are tested for impairment annually. Prepaid patented licenses and computer software are finite-lived intangible assets which are amortized over their estimated useful life. Amortization expenses for finite-lived intangible assets amounted to $145,961, $167,985 and $124,551 for the years ended December 31, 2020, 2019 and 2018, respectively. The Group wrote off the cost and the related amortization of $70,477, $34,400 and $2,320 after the expiration of the computer software for the years ended December 31, 2020, 2019 and 2018, respectively.

The Group expects amortization expense related to its finite-lived intangible assets for the next five years and thereafter to be as follows as of December 31, 2020:

For the years ending December 31,	Amount

2021	$	104,842
2022		102,593
2023		102,593
2024		97,099
2025		80,615
Thereafter		477,115
Total	$	964,857

Long-Term Deposits

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

LONG-TERM DEPOSITS

10. LONG-TERM DEPOSITS

Long-term deposits as of December 31, 2020 and 2019 consisted of:

	December 31, 2020		December 31, 2019

Rental deposits	$	149,175	$	132,043
Prepayments for equipment		147,050		162,563
	$	296,225	$	294,606

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2020 and 2019 consisted of:

	December 31, 2020		December 31, 2019

Deferred bonus and salaries payable	$	2,078,958	$	1,570,324
Research and development expenses payable		750,989		554,791
Professional fees payable		185,838		171,037
Cost of healthcare services payable		104,457		45,234
Insurance expenses payable		33,152		70,811
Deferred rent		-		55,484
Others		87,378		118,846
	$	3,240,772	$	2,586,527

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

INCOME TAXES

12. INCOME TAXES

The Company and its subsidiaries file tax returns separately.

Income taxes

Cayman Islands: under the current laws of the Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.

Hong Kong: in accordance with the relevant tax laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax rate on taxable income. In March 2018, the Hong Kong Government introduced a two-tiered profit tax rate regime by enacting the Inland Revenue (Amendment) (No.3) Ordinance 2018 (the “Ordinance”). Under the two-tiered profits tax rate regime, the first $2 million of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity’s assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%. The subsidiaries registered in Hong Kong did not have assessable profits that were derived Hong Kong during the years ended December 31, 2020, 2019 and 2018. Therefore, no Hong Kong profit tax has been provided for in the periods presented.

United Kingdom: in accordance with the relevant tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within United Kingdom at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 19%. The subsidiary in United Kingdom did not have assessable profits that were derived from United Kingdom during the years ended December 31, 2020, 2019 and 2018. Therefore, no United Kingdom profit tax has been provided for in the periods presented.

Singapore: in accordance with the relevant tax laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 17%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the years ended December 31, 2020, 2019 and 2018. Therefore, no Singapore profit tax has been provided for in the periods presented.

Seychelles: in accordance with the relevant tax laws and regulations of Seychelles, a company registered in the Seychelles is subject to income taxes within Seychelles at the applicable tax rate on taxable income. All the Seychelles subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 25%. The subsidiary in Seychelles did not have assessable profits that were derived from Seychelles during the years ended December 31, 2020, 2019 and 2018. Therefore, no Seychelles profit tax has been provided for in the periods presented.

Samoa: in accordance with the relevant tax laws and regulations of Samoa, a company registered in the Samoa is subject to income taxes within Samoa at the applicable tax rate on taxable income. All the Samoa subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 27%. The subsidiary in Samoa did not have assessable profits that were derived from Samoa during the years ended December 31, 2020, 2019 and 2018. Therefore, no Samoa profit tax has been provided for in the periods presented.

United States (Nevada): in accordance with the relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any tax holiday were subject to income tax at a rate of 21%. The subsidiary in the United States did not have assessable profits that were derived from the United States during the years ended December 31, 2020, 2019 and 2018. Therefore, no United States profit tax has been provided for in the periods presented.

Canada: in accordance with the relevant tax laws and regulations of Canada, a company registered in Canada is subject to income taxes within Canada at the applicable tax rate on taxable income. All the Canada subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 15%. The subsidiary in Canada did not have assessable profits that were derived from Canada during the years ended December 31, 2020, 2019 and 2018. Therefore, no Canada profit tax has been provided for in the periods presented.

Ireland: in accordance with the relevant tax laws and regulations of Ireland, a company registered in Ireland is subject to income taxes within Ireland at the applicable tax rate on taxable income. All the Ireland subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of 12.5%. The subsidiary in Ireland did not have assessable profits that were derived from Ireland during the years ended December 31, 2020, 2019 and 2018. Therefore, no Ireland profit tax has been provided for in the periods presented.

The components of the provision for income taxes expenses are:

Year ended December 31, 2020

Year ended December 31, 2019

Year ended December 31, 2018

Current

Deferred

Total income taxes expense

The reconciliation of income taxes expenses computed at the Hong Kong statutory tax rate applicable to income tax expense is as follows:

	Year ended December 31, 2020			Year ended December 31, 2019			Year ended December 31, 2018

Net income (loss) before tax	$	4,920,167		$	(20,116,938	)	$	(15,134,485	)
Provision for income taxes at Hong Kong statutory income tax rate (16.5%)		811,828			(3,319,294	)		(2,497,190	)
Impact of different tax rates in other jurisdictions		(18,869	)		(91,623	)		(3,066	)
Non-taxable income		(4,281,521	)		(389,714	)		(95,018	)
Non-deductible expenses		79,200			702,433			540,893
Change in valuation allowance		3,409,362			3,098,198			2,054,381
Effective income tax expense	$	-		$	-		$	-

Deferred tax asset, net

Deferred tax assets and deferred tax liabilities reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose and the tax bases used for income tax purpose. The following represents the tax effect of each major type of temporary difference.

	December 31, 2020			December 31, 2019
Deferred tax asset:
Tax loss carry forward	$	9,461,421		$	6,699,345
Share-based payment expenses		497,808			-
		9,959,229			6,699,345
Deferred tax liability:
Depreciation and amortization		(397,669	)		(547,147	)
Net deferred tax assets before valuation allowance		9,561,560			6,152,198
Valuation allowance		(9,561,560	)		(6,152,198	)
Deferred tax asset, net	$	-		$	-

As of December 31, 2020 and 2019, the Group had net operating loss carry-forwards of $57,065,283 and $40,329,428, respectively, including its Hong Kong, Singapore, Seychelles, Samoa, the United States, the United Kingdom, Canada and Ireland operations, which are available to reduce future taxable income. Net operating loss carry forward from Seychelles amounting to $492,715 and $439,345 as of December 31, 2020 and 2019, respectively, are available to be carried forward for 5 years, while all of the other losses can be carried forward indefinitely.

Valuation allowance was provided against deferred tax assets in entities where it was determined, it was more likely than not that the benefits of the deferred tax assets will not be realized. The Group had deferred tax assets which consisted of tax loss carry forward, which can be carried forward to offset future taxable income. The Group maintains a full valuation allowance on its net deferred tax assets. The management determines it is more likely than not that all of its deferred tax assets will not be utilized. The valuation allowance increased by $3,409,362, $3,098,198 and $2,054,381, respectively, for the years ended December 31, 2020, 2019 and 2018.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Related Party Balances and Transactions

12 Months Ended

Dec. 31, 2020

Related Party Balances and Transactions

13. RELATED PARTY BALANCES AND TRANSACTIONS

The following is a list of a director and related parties to which the Group has transactions with:

(a)	Ian Huen, the Chief Executive Officer and an Executive Director of the Group;
(b)	Darren Lui, the President and an Executive Director of the Group
(c)	Clark Cheng, an Executive Director of the Group;
(d)	AENEAS CAPITAL LIMITED, an entity controlled by Ian Huen;
(e)	Aeneas Limited, an entity controlled by Ian Huen;
(f)	Aeneas Group Limited, an entity controlled by Ian Huen;
(g)	Aeneas Management Limited, an entity controlled by Ian Huen;
(h)	Aenco Solutions Limited, an entity controlled by Ian Huen; In 2020, it is no longer the Group’s related party as it is disposed to a third party;
(i)	Aenco Limited, an entity controlled by Ian Huen;
(j)	Aeneas Technology (Hong Kong) Limited, an entity controlled by Ian Huen;
(k)	Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;
(l)	CGY Investment Limited, an entity jointly controlled by Darren Lui;
(m)	ACC Medical Limited, an entity controlled by Clark Cheng;
(n)	Sabrina Khan, the Chief Financial Officer of the Group.

Amounts due from related parties

Amounts due from related parties consisted of the following as of December 31, 2020 and 2019:

	December 31, 2020		December 31, 2019
Current
Aeneas Management Limited	$	-	$	962

Non-current
Jurchen Investment Corporation (Note c)	$	-	$	50,000

Amounts due to related parties

Amounts due to related parties consisted of the following as of December 31, 2020 and 2019:

	December 31, 2020		December 31, 2019
Current
Aeneas Group Limited	$	123,922	$	14,247
Jurchen Investment Corporation		19,454		20,055
Ian Huen		2,110		127
Clark Cheng		401		1,114
Sabrina Khan		39		268
Aenco Solutions Limited		-		5,782
Total	$	145,926	$	41,593

Non-current
Aeneas Group Limited (Note a)	$	1,507,285	$	3,330,472
Jurchen Investment Corporation (Note a)		500,000		3,000,000
	$	2,007,285	$	6,330,472

Related party transactions

Related party transactions consisted of the following for the years ended December 31, 2020, 2019 and 2018:

	Year ended December 31, 2020		Year ended December 31, 2019		Year ended December 31, 2018
Loan from related parties (Note a)
- Aeneas Group Limited	$	500,000	$	3,330,472	$	-
- Jurchen Investment Corporation	$	500,000	$	3,000,000	$	-

Interest expenses (Note a)
- Aeneas Group Limited	$	155,633	$	14,247	$	-
- Jurchen Investment Corporation	$	81,530	$	20,055	$	-

Loan repayment and interest paid to related parties (Note a)
- Aeneas Group Limited	$	2,356,080	$	-	$	-
- Jurchen Investment Corporation	$	3,082,131	$	-	$	-

Consultant, secondment, management and administrative services fees (Note b)
- Aenco Limited	$	746,153	$	830,769	$	-
- Aeneas Technology (Hong Kong) Limited	$	617,794	$	-	$	-
- Aeneas Management Limited	$	231,795	$	698,152	$	-
- CGY Investments Limited	$	169,462	$	-	$	-
- ACC Medical Limited	$	13,018	$	-	$	-
- AENEAS CAPITAL LIMITED	$	-	$	-	$	448,718

Rental expense(Note c)
- Jurchen Investment Corporation	$	96,300	$	227,729	$	207,841

Issuance of tokens for tokens creation, offering and consultancy services (Note d)
- Aenco Solutions Limited	$	-	$	300,000	$	-

Tokens creation, offering and consultancy services expense (Note d)
- Aenco Solutions Limited	$	-	$	192,000	$	-

Prepayment of tokens consultancy services (Note d)
- Aenco Solutions Limited	$	-	$	108,000	$	-

Healthcare services income
- Aeneas Management Limited	$	321	$	1,923	$	-

Note a: On August 13, 2019, the Group entered into financing arrangements with Aeneas Group Limited, a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing the Group to access up to a total $15.0 million in line of credit debt financing. The line of credit will mature on August 12, 2022 and the interest on the outstanding principal indebtedness will be at the rate of 8% per annum. The Group may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty.

Note b: Aenco Limited provided certain information technology services to the Group. For the year ended December 31, 2019, Aenco Limited was entitled to receive a fixed amount of services fees of HKD 540,000 (approximately $69,231) per calendar month with the expiry date on December 31, 2019. The agreement was originally renewed under the same terms with the expiry date on December 31, 2020. The agreement was replaced by another agreement on April 1, 2020. Pursuant to the replaced agreement, Aenco Limited is entitled to receive a fixed amount of services fee of HKD 700,000 (approximately $89,744) per calendar month. On September 30, 2020, the replaced agreement was terminated as mutually agreed.

Aeneas Technology (Hong Kong) Limited provided research to the Group to assist the Group in computerized drug screening process of Smart-ACT^TM platform. Aeneas Technology (Hong Kong) Limited is entitled to receive a fixed amount of research fees of HKD 963,760 (approximately $123,559) per calendar month with the expiry date on October 30, 2021. On September 30, 2020, the agreement was terminated as mutually agreed.

Aeneas Management Limited provided certain documentation and administrative services to the Group. For the year ended December 31, 2019, Aeneas Management Limited was entitled to receive a fixed amount of services fees of HKD 452,000 (approximately $57,949) per calendar month with the expiry date on December 31, 2019. The agreement was originally renewed under the same terms with the expiry date on December 31, 2020. On April 30, 2020, the agreement was terminated as mutually agreed.

CGY Investment Limited provided certain consultancy, advisory and management services to the Group on potential investment projects related to healthcare or R&D platforms. CGY Investment Limited is entitled to receive HK $104,000 (approximately $13,333) per calendar month. The agreement will be remained in effect until 1 month’s notice in writing is given by either party.

ACC Medical Limited provided certain consultancy, advisory, and management services to the Group on clinic operations and other related projects for clinics’ business development. ACC Medical Limited is entitled to receive HK $101,542 (approximately $13,018) per calendar month. The agreement will be remained in effect until 1 month’s notice in writing is given by either party.

AENEAS CAPITAL LIMITED provides certain management and administrative services to the Group. For the year ended December 31, 2018, AENEAS CAPITAL LIMITED was entitled to receive a fixed amount of administrative fees of HKD 500,000 (approximately $64,103) per calendar month. On July 31, 2018, the agreement was terminated as mutually agreed.

Note c: Jurchen Investment Corporation entered into a sub-tenancy agreement with a subsidiary of the Group for the rental arrangement of an office in Hong Kong. For the period February 1, 2018 through January 31, 2021, Jurchen Investment Corporation was entitled to receive a fixed amount of rental fee of HK $130,000 (approximately USD 16,667) per calendar month. In May 2020, Jurchen Investment Corporation and the Group mutually agreed to early terminate the rental agreement and returned the office on May 31, 2020.

Note d: In July 2019, Smart Pharmaceutical Limited Partnership (“SPLP”), a wholly owned subsidiary of the Group, transferred 100,000,000 SMPT token to Aenco Solutions Limited, a related party, in exchange of the services related to token creation and offering and consulting services for five years for an amount of $300,000. On March 5, 2021, all agreements regarding the SMPT tokens, including the agreement between SPLP and Aenco Solutions Limited in exchange of the service to deal with the token creation, have been terminated.

Note e: On April 3, 2018, Aptorum Medical Limited issued 526 shares to Clark Cheng, decreasing the equity interest of the Company from 100% to 95%. On March 29, 2019, Aptorum Medical Limited issued 112 shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from 95% to 94%. On January 2, 2020, Aptorum Medical Limited further issued 115 shares to Clark Cheng in according to the appointment agreement, decreasing the equity interest of the Company from 94% to 93%.

Note f: In April 2018, the Group, AENEAS CAPITAL LIMITED, Aeneas Management Limited and Aeneas Group Limited entered into a net settlement agreement to offset the amounts due from related parties against the amounts due to related parties. Thereby, the Group is released from obligation for a total amount of $164,973, netting off receivables of total amount of $197,878 and collected remaining balance of $32,905.

Lease

12 Months Ended

Dec. 31, 2020

Disclosure Text Block [Abstract]

LEASE

14. LEASE

As of December 31, 2020, the Group has three non-short-term operating leases for office, laboratories and clinic with remaining terms expiring from 2022 through 2023 and a weighted average remaining lease term of 1.5 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%. The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Group would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.

	For the year ended December 31, 2020
Lease cost
Finance lease cost:
Depreciation	$	47,819
Interest on lease liabilities		7,290
Operating lease cost		483,398
Short-term lease cost		68,472
Variable lease cost		-
Sublease income		-
Total lease cost	$	606,979

Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	457,508
Financing cash flows from finance leases		53,845
Right-of-use assets obtained in exchange for new operating lease liabilities		1,107,206
Weighted-average remaining lease term – finance leases		1.9 years
Weighted-average remaining lease term – operating leases		1.5 years
Weighted-average discount rate – finance leases		2.5	%
Weighted-average discount rate – operating leases		8.0	%

The maturity analysis of operating leases liabilities as of December 31, 2020 is as follows:

	December 31, 2020
Remaining periods ending December 31,
2021	$	458,078
2022		149,539
2023		17,143
Total future undiscounted cash flow		624,760
Less: Discount on operating lease liabilities		(37,039	)
Present value of operating lease liabilities		587,721
Less: Current portion of operating lease liabilities		(432,600	)
Non-current portion of operating lease liabilities	$	155,121

On May 14, 2018, the Group leased a vehicle for its operation with a lease term of 54 months, and the lease was classified as a finance lease. The following lists the components of the net present value of finance leases liabilities:

	December 31, 2020
Remaining periods ending December 31,
2021	$	53,845
2022		49,358
Total future undiscounted cash flow		103,203
Less: Discount on finance lease liabilities		(5,884	)
Present value of finance lease liabilities		97,319
Less: Current portion of finance lease liabilities		(49,396	)
Non-current portion of finance lease liabilities	$	47,923

Ordinary Shares

12 Months Ended

Dec. 31, 2020

Stockholders' Equity Note [Abstract]

ORDINARY SHARES

15. ORDINARY SHARES

On June 19, 2019, the Group issued 60,093 Class A Ordinary Shares to warrant holders on a cashless basis. Following the exercise of warrants, there were an aggregate of 6,597,362 Class A Ordinary Shares issued and outstanding as of December 31, 2019.

On February 28, 2020, the Group entered into securities purchase agreement (the “Purchase Agreement”) with certain non-affiliated institutional investors and Jurchen Investment Corporation, the ultimate parent of the Group, pursuant to which the Company agreed to sell a total of 1,351,350 Class A Ordinary Shares and warrants to purchase 1,351,350 of the Class A Ordinary Shares, for gross proceeds of approximately $10 million. At the completion of the offering, approximately $1.0 million offering costs was charged to additional paid-in capital. Each warrant entitled their holders to purchase 1 Class A Ordinary Shares and is exercisable immediately as of the date of issuance at an exercise price of $7.40 per Class A Ordinary Share and expire seven years from the date of issuance. Additionally, the Group issued 43,243 warrants to placement agent on terms substantially the same as the warrants issued to investors, except that the exercise price of the warrants issued to the placement agent is $8.88.

On August 27, 2020, the Group entered into warrant exchange agreements (the “Purchaser Exchange Agreements”) with two non-affiliated purchasers to exchange their warrant of the Company by Class A Ordinary Shares of the Company (the “Purchaser Warrant Exchange”). Pursuant to the Purchaser Exchange Agreements, the Company and the Non-affiliated Purchasers have agreed that in consideration for exchanging in full all of the warrants held by the Non-affiliated Purchasers, the Company will exchange one (1) Class A Ordinary Share for each one (1) Purchaser Exchange Warrant. Total 540,540 Class A Ordinary Shares are issued to two non-affiliated purchasers in exchange for 540,540 warrants. For other warrant holders did not participate in the Purchaser Warrant Exchange, the exercise prices of their respective warrants will be reduced to a nominal amount pursuant to the anti-dilution provisions in such warrants (a “Down Round”). As a result of this Down Round being triggered, the Group recorded a deemed dividend of $755,514 as an decrease to net income attributable to Aptorum Group Limited in computing basic net income per share on the consolidated statements of operations.

On October 2, 2020, the Group completed a public offering, issuing 2,769,231 Class A Ordinary Shares and warrants to purchase an aggregate of 2,769,231 Class A Ordinary Shares, for gross proceeds of approximately $9 million. At the completion of the offering, approximately $1.2 million offering costs was charged to additional paid-in capital. The warrants have an exercise price of $3.25 per Class A Ordinary Share, are exercisable upon issuance and will expire five years from the date of issuance. Additionally, the Group issued 147,538 warrants to placement agent on terms substantially the same as the warrants issued to investors, except that the exercise price of the warrants issued to the placement agent is $4.0625. Following the public offering completed on October 2, 2020, the placement agent of the offering on February 28, 2020 was further received 65,406 warrants as a tail fee, with an exercise price of $3.9 and expire seven years from the date of issuance.

All the above issued warrants are classified as equity in accordance with ASC 815, Derivatives and Hedging. This ASC provides a scope exception from classifying and measuring as a financial liability a contract that would otherwise meet the definition of a derivative if the contract is both (i) indexed to the entity’s own stock and (ii) meets the equity classifications conditions. The Group concluded all above issued warrants should be equity-classified since they contain no provisions which would require the Group to account for the warrants as a derivative liability and therefore were initially measured at fair value in permanent equity with subsequent changes in fair value not measured.

For the year ended December 31, 2020, the Group issued 313,513 and 12,328 Class A Ordinary Shares to warrant holders and share option holders respectively.

Holders of Class A Ordinary Shares and Class B Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time while Class A Ordinary Shares are not convertible under any circumstances.

Share Based Compensation

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

SHARE BASED COMPENSATION

16. SHARE BASED COMPENSATION

Share option plan

A total of 5,500,000 Class A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the 2017 Omnibus Incentive Plan (the “2017 Share Option Plan”). Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal to the lesser of (i) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and (ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments as provided in Section 10 of the 2017 Share Option Plan. Awards will be made pursuant to agreements and may be subject to vesting and other restrictions as determined by the board of directors.

On March 15, 2019, the Group granted 218,222 share options to directors, employees, external consultants and advisors of the Group with an exercise price of $12.91. On March 16, 2020, the Group granted 536,777 share options to directors, employees, external consultants and advisors of the Group with an exercise price of $2.99. On June 1, 2020, the Group granted 148,792 share options to directors and employees of the Group with an exercise price of $3.11. On August 10, 2020, 27,473 options were granted to a consultant with an exercise price is $3.64 per share.

A summary of the option activity as of December 31, 2020 and 2019 and changes during the period is presented below:

	Number of share options			Weighted average exercise price $		Remaining contractual term in years		Aggregate Intrinsic value

Outstanding, January 1, 2020		218,222			12.91		11.51

Granted		713,042			3.04		11.99
Exercised		(12,328	)		4.92				-
Forfeited		(52,427	)		5.80
Cancelled		(148,792	)		12.91
Outstanding, December 31, 2020		717,717			3.76		11.22		-
Exercisable, December 31, 2020		84,671			6.12		9.95		-

	Number of share options		Weighted average exercise price $		Remaining contractual term in years		Aggregate Intrinsic value

Granted, March 15, 2019		218,222		12.91		12.31
Outstanding, December 31, 2019		218,222		12.91		11.51		641,573
Exercisable, December 31, 2019		-		-		-		-

The weighted-average grant date fair value of share option grants during the years ended December 31, 2020 and 2019 was $1.76 and $10.31, respectively. The maximum contractual term for share option was 12.8 years.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions.

	Granted in 2020	Granted in 2019
Expected volatility	88.44%-96.55%	95.02%-95.15%
Risk-free interest rate	0.59%-0.69%	2.46%-2.49%
Expected term from grant date (in years)	5.25-7.29	6.29-7.29
Dividend rate	-	-
Dilution factor	0.9909-1	0.9962
Fair value	$1.55-$2.66	$10.1-$10.52

In connection with the grant of share options to employees and non-employees, the Group recorded share-based compensation charges of $1,191,957 and $286,608, respectively, for the year ended December 31, 2020, and $1,180,477 and $432,355, respectively, for the year ended December 31, 2019.

Non-Controlling Interest

12 Months Ended

Dec. 31, 2020

Noncontrolling Interest [Abstract]

NON-CONTROLLING INTEREST

17. NON-CONTROLLING INTEREST

On March 29, 2019, AML, a majority-owned subsidiary of the Group, issued 112 shares to a director of the Group, which resulted an increase of his equity interest of AML from 5% to 6%. A deficit of $10,672 was reclassified from additional paid-in capital to non-controlling interests within the Group’s consolidated financial statements. On January 2, 2020, AML further issued 115 shares to a director of the Group, which resulted an increase of his equity interest of AML from 6% to 7%. A deficit of $22,325 was reclassified from additional paid-in capital to non-controlling interests within the Group’s consolidated financial statements.

On April 24, 2019, the Smart Pharma Tokens (“SMPT tokens”) was announced to be launched. The SMPT tokens are secured by way of a floating charge against the Project intellectual property (“IP”) to guarantee the distribution of accrued sales-based royalties, sublicensing income or additional cash flow generated by drug candidates developed by the Smart-ACT^TMplatform. SMPT token holders will only be eligible to receive a token distribution if any sales-based royalties, sublicensing income or additional cash flow is generated by drug candidates developed by the Smart-ACT^TM platform, as and when SPLP declares the distribution. Because the token distribution is secured by a security interest in such intellectual property rights, if and when SPLP defaults in its distribution obligations to the SMPT token holders, or in the event of liquidation, dissolution or winding up of SPLP, the floating charge may crystallize into a fixed charge over the charged assets (i.e., the Project IP owned by SPLP).

Total 1 billion SMPT tokens are offered by Smart Pharmaceutical Limited Partnership (“SPLP”), a wholly owned subsidiary of the Group. In July 2019, SPLP transferred 100,000,000 SMPT tokens to Aenco Solutions Limited, a related party of the Group, in exchange for the services related to the tokens creation, offering and 5-year consultancy service. Amount of $300,000 were classified as a component of non-controlling interests within the Group’s consolidated financial statements. The remaining 900,000,000 SMPT tokens are remained and kept by SPLP.

On September 25, 2020, Aptorum Innovation Holding Limited (“AIHL”), a wholly-owned subsidiary of the Group, signed a share subscription and shareholders agreement with certain new individuals and institutions to subscribe ordinary shares of Aptorum Innovation Holding Pte. Limited, a wholly-owned subsidiary of AIHL before the share subscription agreement. As a result, AIHL’s equity interest in Aptorum Innovation Holding Pte. Limited was decreased from 100% to 75%. A deficit of $3,090 was reclassified from additional paid-in capital to non-controlling interests within the Group’s consolidated financial statements.

As of December 31, 2020, non-controlling interest related to 25% equity interest in Aptorum Innovations Holding Pte. Limited, 10% equity interest in mTOR (Hong Kong) Limited, 7% equity interest in Aptorum Medical Limited, 20% equity interest in Acticule Life Sciences Limited, 20% equity interest in the Lanither Life Sciences Limited and the token issued by SPLP in the consolidated balance sheets was deficit of $3,681,858 in total. As of December 31, 2019, non-controlling interest related to 10% equity interest in mTOR (Hong Kong) Limited, 6% equity interest in Aptorum Medical Limited, 20% equity interest in Acticule, 20% equity interest in the Lanither Life Sciences Limited and the token issued by SPLP in the consolidated balance sheets was deficit of $1,509,456 in total.

For the years ended December 31, 2020, 2019 and 2018, non-controlling interest in the consolidated statements of operations were loss of $2,146,687, $1,430,176 and $302,762, respectively.

Net Income (Loss) Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

18. NET INCOME (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted income (loss) per share:

	Year ended December 31, 2020		Year ended December 31, 2019			Year ended December 31, 2018
Numerator:
Net income (loss) attributable to Aptorum Group Limited	$	6,311,340	$	(18,686,762	)	$	(14,831,723	)
Denominator:
Weighted average shares outstanding
– Basic		31,135,882		29,008,445			27,909,788
– Diluted		31,534,473		29,008,445			27,909,788

Net income (loss) per share attributable to Aptorum Group Limited
– Basic	$	0.20	$	(0.64	)	$	(0.53	)
– Diluted	$	0.20	$	(0.64	)	$	(0.53	)

Basic net income (loss) per share is computed by dividing net income (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their effect would be anti-dilutive.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

19. COMMITMENTS AND CONTINGENCIES

Contingent Payment Obligations

The Group has entered into agreements with independent third parties for purchasing office and laboratory equipment. As of December 31, 2020, the Group had non-cancellable purchase commitments of $49,166.

The Group has additional contingency payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or milestone is met.

Milestone payments are to be made upon achievements of certain conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”) approval, first commercial sale of the licensed products, or other achievements. The aggregate amount of the milestone payments that the Group are required to pay up to different achievements of conditions and milestones for all the license agreements signed as of December 31, 2020 are below:

	Amount
Drug molecules: up to the conditions and milestones of
Preclinical to IND filing	$	282,564
From entering phase 1 to before first commercial sale		22,276,410
First commercial sale		14,956,410
Net sales amount more than certain threshold in a year		70,769,231
Subtotal	$	108,284,615

Diagnostics technology: up to the conditions and milestones of
Before FDA approval	$	1,423,360
	$	109,707,975

For the years ended December 31, 2020, 2019 and 2018, the Group incurred $129,203, $nil and $30,000 milestone payments, respectively. For the years ended December 31, 2020, 2019 and 2018, the Group did not incur any royalties or research and development funding, respectively.

Segment Reporting

12 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

SEGMENT REPORTING

20. SEGMENT REPORTING

The Group’s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and accessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. The Group’s long-lived assets are substantially located in Hong Kong and substantially of the Group’s expense is derived from within Hong Kong. Therefore, no geographical segments are presented.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

21. SUBSEQUENT EVENTS

The Group has evaluated subsequent events through the date of issuance of the consolidated financial statements, and except for the following events with material financial impact on the Group’s consolidated financial statements, no other subsequent event is identified that would have required adjustment or disclosure in the consolidated financial statements.

On March 11, 2021, the Company granted total 752,185 share options to employees, directors, external consultants and advisors of the Group in accordance to the 2017 Share Option Plan with an exercise price of $2.76.

On March 26, 2021, the Company entered into a Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright” or the “Sales Agent”), acting as the Company’s sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent Class A Ordinary Shares, par value $1.00 per share for an aggregate offering price of up to $15,000,000.

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Principles of presentation and consolidation

Non-controlling interests

Non-controlling interests represent the equity interests that are not attributable to the Group.

Use of estimates

Foreign currency translation and transaction

Cash

Cash consists of cash on hand and bank deposits, which is unrestricted as to withdraw and use.

Restricted cash

Restricted cash represented time deposits pledged for banking facilities.

Digital currencies

Digital currencies represented BitCoin, Ethereum, or other virtual currencies that the Group purchased and used to settle certain token related expenses.

Digital currencies are included in current assets in the consolidated balance sheets. Digital currencies purchased are recorded at cost.

Inventories

Inventories are stated at lower of cost and net realizable value. Cost is determined using the weighted average method.

Accounts receivable

Marketable securities

Investments in derivatives

Non-marketable investments

Fair value measurement

As a basis for considering such assumptions, a three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:

	●	Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

	●	Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

	●	Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Property, plant and equipment

Depreciation of property, plant and equipment is provided using the straight-line method over their estimated useful lives:

Building		29 years
Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

Upon sale or disposal, the applicable amounts of asset cost and accumulated depreciation are removed from the accounts and the net amount less proceeds from disposal is charged or credited to income.

Other non-current asset

Other non-current assets

Intangible assets

Impairment of long-lived assets

Convertible debts

Deferred offering costs

Deferred offering costs Deferred offering costs consist principally of legal and registration costs in connection with the Group’s public offering. Such costs are deferred until the closing of the offering, at which time the deferred costs are offset against the offering proceeds and charged to additional paid-in capital.

Operating leases [Policy Text Block]

Operating leases

Finance lease

Warrants

Revenue recognition

Cost of healthcare services

Cost of healthcare services rendered represents cost in relation to the medical services provided including the compensation of the physicians and cost of pharmaceutical supplies and medicine.

Research and development expenses

Income taxes

Uncertain tax positions

Comprehensive income or loss

Net income or loss per share

Risks and uncertainties

Recently adopted accounting pronouncements

Recently issued accounting standards which have not yet been adopted

Organization (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of subsidiaries

Name	Incorporation date	Ownership	Place of incorporation	Principle activities
Aptorum Therapeutics Limited	June 30, 2016	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED	May 16, 2017	100%	Hong Kong	Provision of management services to its holding company and fellow subsidiaries
Aptorum Medical Limited	August 28, 2017	93%	Cayman Islands	Provision of medical clinic services
Aptorum Innovations Holding Limited	April 15, 2019	100%	Cayman Islands	Investment holding company
Aptorum Innovations Holding Pte. Limited	June 5, 2019	75%	Singapore	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited	June 30, 2017	80%	Cayman Islands	Research and development of life science and biopharmaceutical products
Claves Life Sciences Limited	August 2, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Nativus Life Sciences Limited	July 7, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Videns Incorporation Limited	March 2, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
mTOR (Hong Kong) Limited	November 4, 2016	90%	Hong Kong	Research and development of life science and biopharmaceutical products
Scipio Life Sciences Limited	July 19, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products
Signate Life Sciences Limited	August 28, 2017	100%	Cayman Islands	Research and development of life science and biopharmaceutical products

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of estimated useful lives

Building		29 years
Computer equipment		3 years
Furniture, fixture, and office and medical equipment		5 years
Leasehold improvements		Shorter of the remaining lease terms or 5 years
Laboratory equipment		5 years
Motor vehicle		5 years

Investment and Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities carried at fair value measured on a recurring basis

December 31, 2020	Level 1		Level 2		Level 3		Total
Current Assets
Marketable securities
Common stocks	$	66,062	$	28,318,882	$	-	$	28,384,944
Investments in derivatives
Warrants		-		-		4,289		4,289
Total assets at fair value	$	66,062	$	28,318,882	$	4,289	$	28,389,233

December 31, 2019	Level 1		Level 2		Level 3		Total
Current Assets
Marketable securities
Common stocks	$	806,778	$	256,333	$	-	$	1,063,111
Investments in derivatives
Warrants		-		-		203,320		203,320
Total assets at fair value	$	806,778	$	256,333	$	203,320	$	1,266,431

Schedule of fair value reconciliation of Level 3 assets

	Warrants
Balance at January 1, 2020	$	203,320
Change in unrealized depreciation		(199,031	)
Balance at December 31, 2020	$	4,289
Net change in unrealized depreciation relating to investments still held at December 31, 2020		(198,549	)

Balance at January 1, 2019	$	115,721
Change in unrealized appreciation		87,599
Balance at December 31, 2019	$	203,320
Net change in unrealized appreciation relating to investments still held at December 31, 2019		87,599

Schedule of quantitative information about the group’s level 3 fair value measurements of investment

December 31,
2020

Valuation technique

Unobservable input

Range

(weighted average)

Warrants

Black-Scholes Model

Estimated time to exit Historical Volatility

6 months 122%

December 31,
2019

Valuation technique

Unobservable input

Range

(weighted average)

Warrants

Black-Scholes Model

Estimated time to exit Historical Volatility

12-18 months 73% - 301%

Schedule of unrealized gains and losses

	Year ended December 31, 2020		Year ended December 31, 2019		Year ended December 31, 2018
Upward adjustments	$	-	$	1,017,468	$	-
Total unrealized gain for non-marketable investments	$	-	$	1,017,468	$	-

Schedule of carrying value of our non-marketable investments

	December 31, 2020		December 31, 2019
Initial cost basis	$	4,079,707	$	6,094,712
Upward adjustments		-		1,017,468
Total carrying value at the end of the year	$	4,079,707	$	7,112,180

Other Receivables and Prepayments (Tables)

12 Months Ended

Dec. 31, 2020

Other Income and Expenses [Abstract]

Schedule of other receivables and prepayments

	December 31, 2020		December 31, 2019

Prepaid insurance	$	82,060	$	154,011
Prepaid service fee		174,114		296,565
Rental deposits		12,022		8,584
Prepaid rental expenses		14,251		37,169
Prepaid research and development expenses		978,044		453,634
Other receivables		74,176		109,714
Others		44,329		19,366
	$	1,378,996	$	1,079,043

Digital Currencies (Tables)

12 Months Ended

Dec. 31, 2020

Digital Currencies [Abstract]

Schedule of additional information about digital currencies

	December 31, 2020		December 31, 2019

Beginning balance	$	1,539	$	-
Purchase of digital currencies		-		200,000
Utilization of digital currencies to settle service fee		-		(245,178	)
Gain on use of digital currencies		-		46,717
Ending balance	$	1,539	$	1,539

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of property, plant and equipment

	December 31, 2020		December 31, 2019

Building	$	-	$	1,488,396
Computer equipment		77,611		76,365
Furniture, fixture, and office and medical equipment		262,664		271,009
Leasehold improvements		542,514		665,546
Laboratory equipment		4,058,538		4,029,640
Motor vehicle		239,093		239,093
Assets in construction		1,899,169		1,899,169
		7,079,589		8,669,218
Less: accumulated depreciation		2,393,266		1,576,183
Property, plant and equipment, net	$	4,686,323	$	7,093,035

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

	December 31, 2020		December 31, 2019
Gross carrying amount
Prepaid unpatented license	$	-	$	200,000
Prepaid patented licenses		1,322,820		1,322,820
Computer software		26,985		97,462
		1,349,805		1,620,282

Less: accumulated amortization
Prepaid patented licenses		360,212		257,619
Computer software		24,736		50,980
		384,948		308,599

Intangible assets, net
Prepaid unpatented license		-		200,000
Prepaid patented licenses		962,608		1,065,201
Computer software		2,249		46,482
Intangible assets, net	$	964,857	$	1,311,683

Schedule of amortization expense related to its finite-lived intangible assets

For the years ending December 31,	Amount

2021	$	104,842
2022		102,593
2023		102,593
2024		97,099
2025		80,615
Thereafter		477,115
Total	$	964,857

Long-Term Deposits (Tables)

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Schedule of long-term deposits

	December 31, 2020		December 31, 2019

Rental deposits	$	149,175	$	132,043
Prepayments for equipment		147,050		162,563
	$	296,225	$	294,606

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2020

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued expenses

	December 31, 2020		December 31, 2019

Deferred bonus and salaries payable	$	2,078,958	$	1,570,324
Research and development expenses payable		750,989		554,791
Professional fees payable		185,838		171,037
Cost of healthcare services payable		104,457		45,234
Insurance expenses payable		33,152		70,811
Deferred rent		-		55,484
Others		87,378		118,846
	$	3,240,772	$	2,586,527

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of provision for income taxes expenses

Year ended December 31, 2020

Year ended December 31, 2019

Year ended December 31, 2018

Current

Deferred

Total income taxes expense

Schedule of income taxes expenses computed at the Hong Kong statutory tax rate

	Year ended December 31, 2020			Year ended December 31, 2019			Year ended December 31, 2018

Net income (loss) before tax	$	4,920,167		$	(20,116,938	)	$	(15,134,485	)
Provision for income taxes at Hong Kong statutory income tax rate (16.5%)		811,828			(3,319,294	)		(2,497,190	)
Impact of different tax rates in other jurisdictions		(18,869	)		(91,623	)		(3,066	)
Non-taxable income		(4,281,521	)		(389,714	)		(95,018	)
Non-deductible expenses		79,200			702,433			540,893
Change in valuation allowance		3,409,362			3,098,198			2,054,381
Effective income tax expense	$	-		$	-		$	-

Schedule of deferred tax asset

	December 31, 2020			December 31, 2019
Deferred tax asset:
Tax loss carry forward	$	9,461,421		$	6,699,345
Share-based payment expenses		497,808			-
		9,959,229			6,699,345
Deferred tax liability:
Depreciation and amortization		(397,669	)		(547,147	)
Net deferred tax assets before valuation allowance		9,561,560			6,152,198
Valuation allowance		(9,561,560	)		(6,152,198	)
Deferred tax asset, net	$	-		$	-

Related Party Balances and Transactions (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of amounts due from related parties

	December 31, 2020		December 31, 2019
Current
Aeneas Management Limited	$	-	$	962

Non-current
Jurchen Investment Corporation (Note c)	$	-	$	50,000

Schedule of amounts due to related parties

	December 31, 2020		December 31, 2019
Current
Aeneas Group Limited	$	123,922	$	14,247
Jurchen Investment Corporation		19,454		20,055
Ian Huen		2,110		127
Clark Cheng		401		1,114
Sabrina Khan		39		268
Aenco Solutions Limited		-		5,782
Total	$	145,926	$	41,593

Non-current
Aeneas Group Limited (Note a)	$	1,507,285	$	3,330,472
Jurchen Investment Corporation (Note a)		500,000		3,000,000
	$	2,007,285	$	6,330,472

Schedule of related party transactions

	Year ended December 31, 2020		Year ended December 31, 2019		Year ended December 31, 2018
Loan from related parties (Note a)
- Aeneas Group Limited	$	500,000	$	3,330,472	$	-
- Jurchen Investment Corporation	$	500,000	$	3,000,000	$	-

Interest expenses (Note a)
- Aeneas Group Limited	$	155,633	$	14,247	$	-
- Jurchen Investment Corporation	$	81,530	$	20,055	$	-

Loan repayment and interest paid to related parties (Note a)
- Aeneas Group Limited	$	2,356,080	$	-	$	-
- Jurchen Investment Corporation	$	3,082,131	$	-	$	-

Consultant, secondment, management and administrative services fees (Note b)
- Aenco Limited	$	746,153	$	830,769	$	-
- Aeneas Technology (Hong Kong) Limited	$	617,794	$	-	$	-
- Aeneas Management Limited	$	231,795	$	698,152	$	-
- CGY Investments Limited	$	169,462	$	-	$	-
- ACC Medical Limited	$	13,018	$	-	$	-
- AENEAS CAPITAL LIMITED	$	-	$	-	$	448,718

Rental expense(Note c)
- Jurchen Investment Corporation	$	96,300	$	227,729	$	207,841

Issuance of tokens for tokens creation, offering and consultancy services (Note d)
- Aenco Solutions Limited	$	-	$	300,000	$	-

Tokens creation, offering and consultancy services expense (Note d)
- Aenco Solutions Limited	$	-	$	192,000	$	-

Prepayment of tokens consultancy services (Note d)
- Aenco Solutions Limited	$	-	$	108,000	$	-

Healthcare services income
- Aeneas Management Limited	$	321	$	1,923	$	-

Lease (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure Text Block [Abstract]

Schedule of total carrying value of our non-marketable investments

	For the year ended December 31, 2020
Lease cost
Finance lease cost:
Depreciation	$	47,819
Interest on lease liabilities		7,290
Operating lease cost		483,398
Short-term lease cost		68,472
Variable lease cost		-
Sublease income		-
Total lease cost	$	606,979

Other information
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	457,508
Financing cash flows from finance leases		53,845
Right-of-use assets obtained in exchange for new operating lease liabilities		1,107,206
Weighted-average remaining lease term – finance leases		1.9 years
Weighted-average remaining lease term – operating leases		1.5 years
Weighted-average discount rate – finance leases		2.5	%
Weighted-average discount rate – operating leases		8.0	%

Schedule of maturity analysis of operating leases liabilities

	December 31, 2020
Remaining periods ending December 31,
2021	$	458,078
2022		149,539
2023		17,143
Total future undiscounted cash flow		624,760
Less: Discount on operating lease liabilities		(37,039	)
Present value of operating lease liabilities		587,721
Less: Current portion of operating lease liabilities		(432,600	)
Non-current portion of operating lease liabilities	$	155,121

	December 31, 2020
Remaining periods ending December 31,
2021	$	53,845
2022		49,358
Total future undiscounted cash flow		103,203
Less: Discount on finance lease liabilities		(5,884	)
Present value of finance lease liabilities		97,319
Less: Current portion of finance lease liabilities		(49,396	)
Non-current portion of finance lease liabilities	$	47,923

Share Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of the option activity

	Number of share options			Weighted average exercise price $		Remaining contractual term in years		Aggregate Intrinsic value

Outstanding, January 1, 2020		218,222			12.91		11.51

Granted		713,042			3.04		11.99
Exercised		(12,328	)		4.92				-
Forfeited		(52,427	)		5.80
Cancelled		(148,792	)		12.91
Outstanding, December 31, 2020		717,717			3.76		11.22		-
Exercisable, December 31, 2020		84,671			6.12		9.95		-

	Number of share options		Weighted average exercise price $		Remaining contractual term in years		Aggregate Intrinsic value

Granted, March 15, 2019		218,222		12.91		12.31
Outstanding, December 31, 2019		218,222		12.91		11.51		641,573
Exercisable, December 31, 2019		-		-		-		-

Schedule of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model

	Granted in 2020	Granted in 2019
Expected volatility	88.44%-96.55%	95.02%-95.15%
Risk-free interest rate	0.59%-0.69%	2.46%-2.49%
Expected term from grant date (in years)	5.25-7.29	6.29-7.29
Dividend rate	-	-
Dilution factor	0.9909-1	0.9962
Fair value	$1.55-$2.66	$10.1-$10.52

Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of basic and diluted income (loss) per share

	Year ended December 31, 2020		Year ended December 31, 2019			Year ended December 31, 2018
Numerator:
Net income (loss) attributable to Aptorum Group Limited	$	6,311,340	$	(18,686,762	)	$	(14,831,723	)
Denominator:
Weighted average shares outstanding
– Basic		31,135,882		29,008,445			27,909,788
– Diluted		31,534,473		29,008,445			27,909,788

Net income (loss) per share attributable to Aptorum Group Limited
– Basic	$	0.20	$	(0.64	)	$	(0.53	)
– Diluted	$	0.20	$	(0.64	)	$	(0.53	)

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Schedule of milestone payments are to be made upon achievements of certain conditions

	Amount
Drug molecules: up to the conditions and milestones of
Preclinical to IND filing	$	282,564
From entering phase 1 to before first commercial sale		22,276,410
First commercial sale		14,956,410
Net sales amount more than certain threshold in a year		70,769,231
Subtotal	$	108,284,615

Diagnostics technology: up to the conditions and milestones of
Before FDA approval	$	1,423,360
	$	109,707,975

Organization (Details) - Schedule of subsidiaries	12 Months Ended
Organization (Details) - Schedule of subsidiaries	Dec. 31, 2020
Aptorum Therapeutics Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Jun. 30, 2016
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
APTUS MANAGEMENT LIMITED [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	May 16, 2017
Ownership	100.00%
Place of incorporation	Hong Kong
Principle activities	Provision of management services to its holding company and fellow subsidiaries
Aptorum Medical Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Aug. 28, 2017
Ownership	93.00%
Place of incorporation	Cayman Islands
Principle activities	Provision of medical clinic services
Aptorum Innovations Holding Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Apr. 15, 2019
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Investment holding company
Aptorum Innovations Holding Pte. Ltd. [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Jun. 05, 2019
Ownership	75.00%
Place of incorporation	Singapore
Principle activities	Research and development of life science and biopharmaceutical products
Acticule Life Sciences Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Jun. 30, 2017
Ownership	80.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
Claves Life Sciences Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Aug. 02, 2017
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
Nativus Life Sciences Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Jul. 07, 2017
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
Videns Incorporation Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Mar. 02, 2017
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
mTOR (Hong Kong) Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Nov. 04, 2016
Ownership	90.00%
Place of incorporation	Hong Kong
Principle activities	Research and development of life science and biopharmaceutical products
Scipio Life Sciences Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Jul. 19, 2017
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products
Signate Life Sciences Limited [Member]
Organization (Details) - Schedule of subsidiaries [Line Items]
Incorporation date	Aug. 28, 2017
Ownership	100.00%
Place of incorporation	Cayman Islands
Principle activities	Research and development of life science and biopharmaceutical products

Liquidity (Details) - USD ($)	12 Months Ended
Liquidity (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Liquidity (Details) [Line Items]
Net operating loss	$ (20,275,541)
Net operation cash outflow	(15,931,913)	$ (13,382,633)	$ (10,035,531)
Accumulated deficit	(30,489,126)	(37,555,980)
Restricted cash	130,125	$ 104,170
Line of Credit [Member]
Liquidity (Details) [Line Items]
Restricted cash	2,400,000
Line of Credit [Member]
Liquidity (Details) [Line Items]
Unrestricted cash	$ 10,700,000

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 24, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Amortization expenses		$ 59,833	$ 59,834	$ 59,833
Group repurchased its convertible debts	$ 13,600,000
Convertible debts with carrying amount	13,500,000
Gain on extinguishment on convertible debts	1,200,000		1,198,490
Intrinsic value	$ 1,300,000
Measure the tax benefit		50.00%
Operating losses are available to be carried forward		5 years
Operating lease right-of-use assets		$ 547,389			$ 959,641
Operating lease liabilities		$ 432,600			$ 982,288
Computer software [Member] \| Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Useful life intangible assets		17 years
Computer software [Member] \| Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Useful life intangible assets		20 years

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives	12 Months Ended
	Dec. 31, 2020
Building [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Estimated useful lives	29 years
Computer equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Estimated useful lives	3 years
Furniture, fixture, and office and medical equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Estimated useful lives	5 years
Leasehold improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Leasehold improvements, estimated useful lives	Shorter of the remaining lease terms or 5 years
Laboratory equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Estimated useful lives	5 years
Motor vehicle [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Estimated useful lives	5 years

Investment and Fair Value Measurement (Details)	12 Months Ended
Investment and Fair Value Measurement (Details)	Dec. 31, 2020 USD ($)
Fair Value Disclosures [Abstract]
Non-marketable investments	$ 2,015,005
Transferred marketable investments.	$ 1,017,468

Investment and Fair Value Measurement (Details) - Schedule of assets and liabilities carried at fair value measured on a recurring basis - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Marketable securities
Total assets at fair value	$ 28,389,233	$ 1,266,431
Common Stock [Member]
Marketable securities
Total assets at fair value	28,384,944	1,063,111
Warrant [Member]
Marketable securities
Total assets at fair value	4,289	203,320
Level 1 [Member]
Marketable securities
Total assets at fair value	66,062	806,778
Level 1 [Member] \| Common Stock [Member]
Marketable securities
Total assets at fair value	66,062	806,778
Level 2 [Member]
Marketable securities
Total assets at fair value	28,318,882	256,333
Level 2 [Member] \| Common Stock [Member]
Marketable securities
Total assets at fair value	28,318,882	256,333
Level 3 [Member]
Marketable securities
Total assets at fair value	4,289	203,320
Level 3 [Member] \| Warrant [Member]
Marketable securities
Total assets at fair value	$ 4,289	$ 203,320

Investment and Fair Value Measurement (Details) - Schedule of fair value reconciliation of Level 3 assets - Fair value recurring [Member] - Warrants [Member] - Level 3 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 203,320	$ 115,721
Ending Balance	4,289	203,320
Change in unrealized appreciation (depreciation)	(199,031)	87,599
Net change in unrealized depreciation relating to investments still held	$ (198,549)	$ 87,599

Investment and Fair Value Measurement (Details) - Schedule of quantitative information about the group’s level 3 fair value measurements of investment - Warrant [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation technique	Black-Scholes Model	Black-Scholes Model
Unobservable input	Estimated time to exit Historical Volatility	Estimated time to exit Historical Volatility
Range (weighted average)	6 months 122%	12-18 months 73% - 301%

Investment and Fair Value Measurement (Details) - Schedule of unrealized gains and losses - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of unrealized gains and losses [Abstract]
Upward adjustments		$ 1,017,468
Total unrealized gain for non-marketable investments		$ 1,017,468

Investment and Fair Value Measurement (Details) - Schedule of carrying value of our non-marketable investments - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of carrying value of our non-marketable investments [Abstract]
Initial cost basis	$ 4,079,707	$ 6,094,712
Upward adjustments		1,017,468
Total carrying value at the end of the period	$ 4,079,707	$ 7,112,180

Other Receivables and Prepayments (Details) - Schedule of other receivables and prepayments - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of other receivables and prepayments [Abstract]
Prepaid insurance	$ 82,060	$ 154,011
Prepaid service fee	174,114	296,565
Rental deposits	12,022	8,584
Prepaid rental expenses	14,251	37,169
Prepaid research and development expenses	978,044	453,634
Other receivables	74,176	109,714
Others	44,329	19,366
Total	$ 1,378,996	$ 1,079,043

Digital Currencies (Details) - Schedule of additional information about digital currencies - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of additional information about digital currencies [Abstract]
Beginning balance	$ 1,539
Ending balance	1,539	1,539
Purchase of digital currencies		200,000
Utilization of digital currencies to settle service fee		(245,178)
Gain on use of digital currencies		$ 46,717

Property, Plant and Equipment, Net (Details) - USD ($)	1 Months Ended	10 Months Ended	12 Months Ended
Property, Plant and Equipment, Net (Details) - USD ($)	Jul. 20, 2020	Dec. 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment, Net (Details) [Line Items]
Depreciation expenses		$ 1,128,867		$ 1,071,799	$ 497,908
Impairment loss			$ 330,445
Other operating expenses			$ 50,197
HONG KONG
Property, Plant and Equipment, Net (Details) [Line Items]
Sale of property in related parties	$ 1,100,000

Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 7,079,589	$ 8,669,218
Less: accumulated depreciation	2,393,266	1,576,183
Property, plant and equipment, net	4,686,323	7,093,035
Building [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		1,488,396
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	77,611	76,365
Furniture, fixture, and office and medical equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	262,664	271,009
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	542,514	665,546
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,058,538	4,029,640
Motor vehicle [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	239,093	239,093
Assets in construction [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,899,169	$ 1,899,169

Intangible Assets, Net (Details) - USD ($)	12 Months Ended
Intangible Assets, Net (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment loss	$ 200,000
Amortization expenses for finite-lived intangible assets	145,961	$ 167,985	$ 124,551
Wrote off of cost related amortization	$ 70,477	$ 34,400	$ 2,320

Intangible Assets, Net (Details) - Schedule of intangible assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Gross carrying amount	$ 1,349,805	$ 1,620,282
Less: accumulated amortization	384,948	308,599
Intangible assets, net	964,857	1,311,683
Prepaid unpatented license [Member]
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Gross carrying amount		200,000
Intangible assets, net		200,000
Prepaid patented licenses [Member]
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Gross carrying amount	1,322,820	1,322,820
Less: accumulated amortization	360,212	257,619
Intangible assets, net	962,608	1,065,201
Computer software [Member]
Intangible Assets, Net (Details) - Schedule of intangible assets [Line Items]
Gross carrying amount	26,985	97,462
Less: accumulated amortization	24,736	50,980
Intangible assets, net	$ 2,249	$ 46,482

Intangible Assets, Net (Details) - Schedule of amortization expense related to its finite-lived intangible assets	Dec. 31, 2020 USD ($)
Schedule of amortization expense related to its finite-lived intangible assets [Abstract]
2021	$ 104,842
2022	102,593
2023	102,593
2024	97,099
2025	80,615
Thereafter	477,115
Total	$ 964,857

Long-Term Deposits (Details) - Schedule of long-term deposits - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of long-term deposits [Abstract]
Rental deposits	$ 149,175	$ 132,043
Prepayments for equipment	147,050	162,563
Total	$ 296,225	$ 294,606

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable and accrued expenses - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule of accounts payable and accrued expenses [Abstract]
Deferred bonus and salaries payable	$ 2,078,958	$ 1,570,324
Research and development expenses payable	750,989	554,791
Professional fees payable	185,838	171,037
Cost of healthcare services payable	104,457	45,234
Insurance expenses payable	33,152	70,811
Deferred rent		55,484
Others	87,378	118,846
Accounts payable and accrued expenses	$ 3,240,772	$ 2,586,527

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes (Details) [Line Items]
Net operating loss carry-forwards	$ 57,065,283	$ 40,329,428
Valuation allowance increased	$ 3,409,362	3,098,198	$ 2,054,381
Hong Kong [Member]
Income Taxes (Details) [Line Items]
Income tax, description	Under the two-tiered profits tax rate regime, the first $2 million of assessable profits of qualifying corporations is taxed at 8.25% and the remaining assessable profits at 16.5%. The Ordinance is effective from the year of assessment 2018-2019. According to the policy, if no election has been made, the whole of the taxpaying entity’s assessable profits will be chargeable to Profits Tax at the rate of 16.5% or 15%, as applicable. Because the preferential tax treatment is not elected by the Group, all the subsidiaries registered in Hong Kong are subject to income tax at a rate of 16.5%.
United Kingdom [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	19.00%
Singapore [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	17.00%
Seychelles [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	25.00%
Net operating loss carry-forwards	$ 492,715	$ 439,345
Tax carried forward other losses	5 years
Samoa [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	27.00%
United States (Nevada) [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	21.00%
Canada [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	15.00%
Ireland [Member]
Income Taxes (Details) [Line Items]
Income tax rate percentage	12.50%

Income Taxes (Details) - Schedule of provision for income taxes expenses - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of provision for income taxes expenses [Abstract]
Current
Deferred
Total income taxes expense

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes (Details) - Schedule of income taxes expenses computed at the Hong Kong statutory tax rate - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of income taxes expenses computed at the Hong Kong statutory tax rate [Abstract]
Net income (loss) before tax	$ 4,920,167	$ (20,116,938)	$ (15,134,485)
Provision for income taxes at Hong Kong statutory income tax rate (16.5%)	811,828	(3,319,294)	(2,497,190)
Impact of different tax rates in other jurisdictions	(18,869)	(91,623)	(3,066)
Non-taxable income	(4,281,521)	(389,714)	(95,018)
Non-deductible expenses	79,200	702,433	540,893
Change in valuation allowance	3,409,362	3,098,198	2,054,381
Effective income tax expense

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes (Details) - Schedule of deferred tax asset - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax asset:
Tax loss carry forward	$ 9,461,421	$ 6,699,345
Share-based payment expenses	497,808
Deferred tax asset	9,959,229	6,699,345
Deferred tax liability:
Depreciation and amortization	(397,669)	(547,147)
Net deferred tax assets before valuation allowance	9,561,560	6,152,198
Valuation allowance	(9,561,560)	(6,152,198)
Deferred tax asset, net

Related Party Balances and Transactions (Details)				12 Months Ended
Related Party Balances and Transactions (Details)	Aug. 13, 2019	Jul. 31, 2019	Apr. 30, 2018	Dec. 31, 2020 USD ($)	Dec. 31, 2020 HKD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 HKD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 HKD ($)	Jan. 02, 2020 shares	Mar. 29, 2019 shares	Apr. 03, 2018 shares
Related Party Balances and Transactions (Details) [Line Items]
Description of rental fee				Jurchen Investment Corporation was entitled to receive a fixed amount of rental fee of HK $130,000 (approximately USD 16,667) per calendar month.	Jurchen Investment Corporation was entitled to receive a fixed amount of rental fee of HK $130,000 (approximately USD 16,667) per calendar month.
Related party transaction, description		Smart Pharmaceutical Limited Partnership (“SPLP”), a wholly owned subsidiary of the Group, transferred 100,000,000 SMPT token to Aenco Solutions Limited, a related party, in exchange of the services related to token creation and offering and consulting services for five years for an amount of $300,000.
Shares issued \| shares										115
Aeneas Group Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Line of credit facility, description	the ultimate parent of the Group, allowing the Group to access up to a total $15.0 million in line of credit debt financing. The line of credit will mature on August 12, 2022 and the interest on the outstanding principal indebtedness will be at the rate of 8% per annum.
Aenco Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees				$ 89,744		$ 69,231
Aeneas Technology (Hong Kong) Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Research fee				$ 123,559
Expiry date				Oct. 30, 2021	Oct. 30, 2021
Aeneas Management Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees						$ 57,949
CGY Investments Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees				$ 13,333
ACC Medical Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees				$ 13,018
AENEAS CAPITAL LIMITED [Member]
Related Party Balances and Transactions (Details) [Line Items]
Administrative fees								$ 64,103
Description of obligation			the Group, AENEAS CAPITAL LIMITED, Aeneas Management Limited and Aeneas Group Limited entered into a net settlement agreement to offset the amounts due from related parties against the amounts due to related parties. Thereby, the Group is released from obligation for a total amount of $164,973, netting off receivables of total amount of $197,878 and collected remaining balance of $32,905.
Clark Cheng [Member]
Related Party Balances and Transactions (Details) [Line Items]
Shares issued \| shares										115	112	526
Clark Cheng [Member] \| Maximum [Member]
Related Party Balances and Transactions (Details) [Line Items]
Increase decrease equity interest, percentage										94.00%	95.00%
Clark Cheng [Member] \| Minimum [Member]
Related Party Balances and Transactions (Details) [Line Items]
Increase decrease equity interest, percentage										93.00%	94.00%
Aptorum Medical Limited [Member] \| Maximum [Member]
Related Party Balances and Transactions (Details) [Line Items]
Ownership of aeneas limited and its subsidiary												100.00%
Aptorum Medical Limited [Member] \| Minimum [Member]
Related Party Balances and Transactions (Details) [Line Items]
Ownership of aeneas limited and its subsidiary												95.00%
HKD [Member] \| Aenco Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees					$ 700,000		$ 540,000
HKD [Member] \| Aeneas Technology (Hong Kong) Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Research fee					963,760
HKD [Member] \| Aeneas Management Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees							$ 452,000
HKD [Member] \| CGY Investments Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees					104,000
HKD [Member] \| ACC Medical Limited [Member]
Related Party Balances and Transactions (Details) [Line Items]
Services fees					$ 101,542
HKD [Member] \| AENEAS CAPITAL LIMITED [Member]
Related Party Balances and Transactions (Details) [Line Items]
Administrative fees									$ 500,000

Related Party Balances and Transactions (Details) - Schedule of amounts due from related parties - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Aeneas Management Limited [Member]
Current
Amounts due from related parties, Current		$ 962
Jurchen Investment Corporation [Member]
Non-current
Amounts due from related parties, Non-current		$ 50,000

Related Party Balances and Transactions (Details) - Schedule of amounts due to related parties - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current
Amounts due to related parties, Current	$ 145,926	$ 41,593
Non-current
Amounts due to related parties, Non-current	2,007,285	6,330,472
Aeneas Group Limited [Member]
Current
Amounts due to related parties, Current	123,922	14,247
Non-current
Amounts due to related parties, Non-current	1,507,285	3,330,472
Jurchen Investment Corporation [Member]
Current
Amounts due to related parties, Current	19,454	20,055
Ian Huen [Member]
Current
Amounts due to related parties, Current	2,110	127
Clark Cheng [Member]
Current
Amounts due to related parties, Current	401	1,114
Sabrina Khan [Member]
Current
Amounts due to related parties, Current	39	268
Aenco Solutions Limited [Member]
Current
Amounts due to related parties, Current		5,782
Jurchen Investment Corporation [Member]
Non-current
Amounts due to related parties, Non-current	$ 500,000	$ 3,000,000

Related Party Balances and Transactions (Details) - Schedule of related party transactions - USD ($)

12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Aeneas Group Limited [Member]

Loan from related parties

^[1]

$ 500,000

$ 3,330,472

Interest expenses

^[1]

155,633

14,247

Loan repayment and interest paid to related parties

^[1]

2,356,080

Jurchen Investment Corporation [Member]

Loan from related parties

^[1]

500,000

3,000,000

Interest expenses

^[1]

81,530

20,055

Loan repayment and interest paid to related parties

^[1]

3,082,131

Rental expense

^[2]

96,300

227,729

207,841

Aenco Limited [Member]

Consultant, secondment, management and administrative services fees

^[3]

746,153

830,769

Aeneas Technology (Hong Kong) Limited [Member]

Consultant, secondment, management and administrative services fees

^[3]

617,794

Aeneas Management Limited [Member]

Consultant, secondment, management and administrative services fees

^[3]

231,795

698,152

Healthcare services income

321

1,923

CGY Investments Limited [Member]

Consultant, secondment, management and administrative services fees

^[3]

169,462

ACC Medical Limited [Member]

Consultant, secondment, management and administrative services fees

^[3]

13,018

AENEAS CAPITAL LIMITED [Member]

Consultant, secondment, management and administrative services fees

^[3]

448,718

Aenco Solutions Limited [Member]

Issuance of tokens for tokens creation, offering an consultancy services

^[4]

300,000

Tokens creation, offering an consultancy services expense

^[4]

192,000

Prepayment of tokens consultancy services

^[4]

$ 108,000

[1]	On August 13, 2019, the Group entered into financing arrangements with Aeneas Group Limited, a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing the Group to access up to a total $15.0 million in line of credit debt financing. The line of credit will mature on August 12, 2022 and the interest on the outstanding principal indebtedness will be at the rate of 8% per annum. The Group may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty.
[2]	Jurchen Investment Corporation entered into a sub-tenancy agreement with a subsidiary of the Group for the rental arrangement of an office in Hong Kong. For the period February 1, 2018 through January 31, 2021, Jurchen Investment Corporation was entitled to receive a fixed amount of rental fee of HK$130,000 (approximately USD16,667) per calendar month. In May 2020, Jurchen Investment Corporation and the Group mutually agreed to early terminate the rental agreement and returned the office on May 31, 2020.
[3]	Aenco Limited provided certain information technology services to the Group. For the year ended December 31, 2019, Aenco Limited was entitled to receive a fixed amount of services fees of HKD540,000 (approximately $69,231) per calendar month with the expiry date on December 31, 2019. The agreement was originally renewed under the same terms with the expiry date on December 31, 2020. The agreement was replaced by another agreement on April 1, 2020. Pursuant to the replaced agreement, Aenco Limited is entitled to receive a fixed amount of services fee of HKD700,000 (approximately $89,744) per calendar month. On September 30, 2020, the replaced agreement was terminated as mutually agreed.
[4]	In July 2019, Smart Pharmaceutical Limited Partnership, a wholly owned subsidiary of the Group, transferred 100,000,000 SMPT token to Aenco Solutions Limited, a related party, in exchange of the services related to token creation and offering and consulting services for five years for an amount of $300,000.

Lease (Details)	Dec. 31, 2020
Disclosure Text Block [Abstract]
Weighted average remaining lease term	1 year 6 months
Weighted average discount rates	8.00%

Lease (Details) - Schedule of components of finance leases obligation	12 Months Ended
	Dec. 31, 2020 USD ($)
Finance lease cost:
Depreciation	$ 47,819
Interest on lease liabilities	7,290
Operating lease cost	483,398
Short-term lease cost	68,472
Variable lease cost
Sublease income
Total lease cost	606,979
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	457,508
Financing cash flows from finance leases	53,845
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,107,206
Weighted-average remaining lease term – finance leases	1 year 328 days
Weighted-average remaining lease term – operating leases	1 year 6 months
Weighted-average discount rate – finance leases	2.50%
Weighted-average discount rate – operating leases	8.00%

Lease (Details) - Schedule of maturity analysis of operating leases liabilities - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of maturity analysis of operating leases liabilities [Abstract]
2021	$ 458,078
2022	149,539
2023	17,143
Total future undiscounted cash flow	624,760
Less: Discount on operating lease liabilities	(37,039)
Present value of operating lease liabilities	587,721
Less: Current portion of operating lease liabilities	(432,600)
Non-current portion of operating lease liabilities	155,121
2021	53,845
2022	49,358
Total future undiscounted cash flow	103,203
Less: Discount on finance lease liabilities	(5,884)
Present value of finance lease liabilities	97,319
Less: Current portion of finance lease liabilities	(49,396)
Non-current portion of finance lease liabilities	$ 47,923	$ 97,319

Ordinary Shares (Details) - USD ($)		1 Months Ended
Ordinary Shares (Details) - USD ($)	Oct. 02, 2020	Aug. 27, 2020	Feb. 28, 2020	Dec. 31, 2020	Jan. 02, 2020	Dec. 31, 2019	Jun. 19, 2019
Ordinary Shares (Details) [Line Items]
Shares issued					115
Ordinary shares, issued		540,540
Gross proceeds (in Dollars)			$ 10,000,000
Excercise price per share (in Dollars per share)	$ 4.0625
Issuance of expire years			7 years
Issuance of warrants (in Dollars)	$ 147,538		$ 43,243
Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) (in Dollars)			$ 8.88
Deemed dividend (in Dollars)		$ 755,514
Ordinary shares, description	Following the public offering completed on October 2, 2020, the placement agent of the offering on February 28, 2020 was further received 65,406 warrants as a tail fee, with an exercise price of $3.9 and expire seven years from the date of issuance.
Initial Public Offering [Member]
Ordinary Shares (Details) [Line Items]
Warrants to purchase shares	2,769,231
Shares issued, par value (in Dollars per share)			$ 1.0
Class A Ordinary Shares [Member]
Ordinary Shares (Details) [Line Items]
Ordinary shares, issued				11,584,324		6,597,362
Sale of ordinary shares			1,351,350
Warrants to purchase shares			1,351,350
Gross proceeds (in Dollars)	$ 9,000,000
Purchase of excercisable warrant shares			1
Excercise price per share (in Dollars per share)	$ 3.25		$ 7.40
Issuance of expire years	5 years
Non-affiliated purchasers in exchange of warrants		540,540
Class A Ordinary Shares [Member] \| Warrant Holders [Member]
Ordinary Shares (Details) [Line Items]
Shares issued							60,093
Class A Ordinary Shares [Member] \| Initial Public Offering [Member]
Ordinary Shares (Details) [Line Items]
Ordinary shares, issued						6,597,362
Issuance of public offering (in Dollars)	$ 2,769,231
Offering costs (in Dollars)	$ 1,200,000
Class A Ordinary Shares [Member] \| Shares Warrant Holders [Member]
Ordinary Shares (Details) [Line Items]
Ordinary shares, issued				313,513
Class A Ordinary Shares [Member] \| Share Option Holders [Member]
Ordinary Shares (Details) [Line Items]
Ordinary shares, issued				12,328

Share Based Compensation (Details) - USD ($)			1 Months Ended		12 Months Ended
Share Based Compensation (Details) - USD ($)	Aug. 10, 2020	Mar. 15, 2019	Jun. 01, 2020	Mar. 16, 2020	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2020
Share Based Compensation (Details) [Line Items]
Total shares issued (in Shares)							115
Options granted (in Shares)					713,042	218,222
Weighted-average grant date fair value of share option grants					$ 3.04	$ 12.91
Maximum contractual term					11 years 186 days
2017 Share Option Plan [Member]
Share Based Compensation (Details) [Line Items]
Weighted-average grant date fair value of share option grants					$ 1.76	$ 10.31
Maximum contractual term					12 years 292 days
Directors, Employees, External Consultants and Advisors [Member] \| 2017 Share Option Plan [Member]
Share Based Compensation (Details) [Line Items]
Options granted (in Shares)	27,473	218,222	148,792	536,777
Stock option exercise price	$ 3.64	$ 12.91	$ 3.11	$ 2.99
Employees [Member]
Share Based Compensation (Details) [Line Items]
Share-based compensation charges (in Dollars)					$ 1,191,957	$ 286,608
Non-employees [Member]
Share Based Compensation (Details) [Line Items]
Share-based compensation charges (in Dollars)					$ 1,180,477	$ 432,355
Class A Ordinary Shares [Member] \| 2017 Share Option Plan [Member]
Share Based Compensation (Details) [Line Items]
Total shares issued (in Shares)					5,500,000
Stock option related, description					(i) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding December 31, and (ii) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all cases to adjustments as provided in Section 10 of the 2017 Share Option Plan.

Share Based Compensation (Details) - Schedule of the option activity - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of the option activity [Abstract]
Number of share options, Outstanding Beginning	218,222
Weighted average exercise price, Outstanding Beginning	$ 12.91
Remaining contractual term in years, Outstanding Beginning	11 years 186 days
Number of share options, Outstanding, Granted	713,042	218,222
Weighted average exercise price, Granted	$ 3.04	$ 12.91
Remaining contractual term in years, Granted	11 years 361 days	12 years 113 days
Number of share options, Outstanding, Exercised	(12,328)
Weighted average exercise price, Exercised	$ 4.92
Aggregate Intrinsic value, Exercised
Number of share options, Outstanding, Forfeited	(52,427)
Weighted average exercise price, Forfeited	$ 5.80
Number of share options, Outstanding, Cancelled	(148,792)
Weighted average exercise price, Cancelled	$ 12.91
Number of share options, Outstanding, Outstanding, Ending	717,717	218,222
Weighted average exercise price, Outstanding, Ending	$ 3.76	$ 12.91
Remaining contractual term in years, Outstanding, Ending	11 years 80 days	11 years 186 days
Aggregate Intrinsic value, Ending		$ 641,573
Number of share options, Outstanding,Exercisable	84,671
Weighted average exercise price, Exercisable	$ 6.12
Remaining contractual term in years, Exercisable	9 years 346 days
Aggregate Intrinsic value, Exercisable

Share Based Compensation (Details) - Schedule of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model [Abstract]
Expected volatility, minimum	88.44%	95.02%
Expected volatality, maximum	96.55%	95.15%
Risk-free interest rate, minimum	0.59%	2.46%
Risk-free interest rate, maximum	0.69%	2.49%
Expected term from grant date (in years), minimum	5 years 3 months	6 years 105 days
Expected term from grant date (in years), maximum	7 years 105 days	7 years 105 days
Dividend rate
Dilution factor, minimum (in Dollars per share)	$ 0.9909
Dilution factor, maximum (in Dollars per share)	1
Dilution factor (in Dollars per share)		$ 0.9962
Fair value, minimum (in Dollars per share)	1.55	10.1
Fair value, maximum (in Dollars per share)	$ 2.66	$ 10.52

Non-Controlling Interest (Details) - USD ($)	12 Months Ended
Non-Controlling Interest (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 25, 2020	Jan. 02, 2020	Mar. 29, 2019
Non-Controlling Interest (Details) [Line Items]
Shares issued (in Shares)					115
Related party description	Total 1 billion SMPT tokens are offered by Smart Pharmaceutical Limited Partnership (“SPLP”), a wholly owned subsidiary of the Group. In July 2019, SPLP transferred 100,000,000 SMPT tokens to Aenco Solutions Limited, a related party of the Group, in exchange for the services related to the tokens creation, offering and 5-year consultancy service. Amount of $300,000 were classified as a component of non-controlling interests within the Group’s consolidated financial statements. The remaining 900,000,000 SMPT tokens are remained and kept by SPLP.
Non controlling interest (in Dollars)	$ (3,681,858)	$ (1,509,456)
Net loss attributable to non-controlling interests (in Dollars)	$ 2,146,687	$ 1,430,176	$ 302,762
Aptorum Medical Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Shares issued (in Shares)						112
Non-controlling interest rate	7.00%	6.00%
Reclassified from additional paid-in capital to non-controlling interests (in Dollars)					$ 22,325	$ 10,672
Aptorum Innovation Holding Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate	25.00%
Reclassified from additional paid-in capital to non-controlling interests (in Dollars)				$ 3,090
mTOR (Hong Kong) Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate	10.00%	10.00%
Acticule Life Sciences Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate	20.00%
Lanither Life Sciences Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate	20.00%	20.00%
Acticule [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate		20.00%
Minimum [Member] \| Aptorum Medical Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate						5.00%
Increase decrease equity interest percentage					6.00%
Minimum [Member] \| Aptorum Innovation Holding Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Increase decrease equity interest percentage				75.00%
Maximum [Member] \| Aptorum Medical Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Non-controlling interest rate						6.00%
Increase decrease equity interest percentage					7.00%
Maximum [Member] \| Aptorum Innovation Holding Limited [Member]
Non-Controlling Interest (Details) [Line Items]
Increase decrease equity interest percentage				100.00%

Net Income (Loss) Per Share (Details) - Schedule of basic and diluted income (loss) per share - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Numerator:
Net income (loss) attributable to Aptorum Group Limited	$ 6,311,340	$ (18,686,762)	$ (14,831,723)
Denominator:
– Basic	31,135,882	29,008,445	27,909,788
– Diluted	31,534,473	29,008,445	27,909,788
Net income (loss) per share attributable to Aptorum Group Limited
– Basic	$ 0.20	$ (0.64)	$ (0.53)
– Diluted	$ 0.20	$ (0.64)	$ (0.53)

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Non-cancellable purchase commitments	$ 49,166
Milestone payments	$ 129,203		$ 30,000

Commitments and Contingencies (Details) - Schedule of milestone payments are to be made upon achievements of certain conditions	Dec. 31, 2020 USD ($)
Drug molecules: up to the conditions and milestones of
Preclinical to IND filing	$ 282,564
From entering phase 1 to before first commercial sale	22,276,410
First commercial sale	14,956,410
Net sales amount more than certain threshold in a year	70,769,231
Subtotal	108,284,615
Diagnostics technology: up to the conditions and milestones of
Before FDA approval	1,423,360
Total	$ 109,707,975

Segment Reporting (Details)	12 Months Ended
Segment Reporting (Details)	Dec. 31, 2020
Segment Reporting [Abstract]
Number of reportable segments	1

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)		1 Months Ended
	Mar. 11, 2021	Mar. 26, 2021
2017 Share Option Plan [Member]
Subsequent Events (Details) [Line Items]
Share options granted (in Shares)	752,185
Exercise price	$ 2.76
Class A Ordinary Shares [Member] \| Sales Agreement [Member]
Subsequent Events (Details) [Line Items]
Common stock par value		$ 1.00
Aggregate offering price (in Dollars)		$ 15,000,000